FR2689017B1
(en)
*
|
1992-03-31 |
1994-05-27 |
Mtc Medical |
MEDICAL OR VETERINARY INJECTION APPARATUS.
|
US5383851A
(en)
*
|
1992-07-24 |
1995-01-24 |
Bioject Inc. |
Needleless hypodermic injection device
|
US5405333A
(en)
*
|
1992-12-28 |
1995-04-11 |
Richmond; Frank M. |
Liquid medicament bag with needleless connector fitting using boat assembly
|
US6206860B1
(en)
|
1993-07-28 |
2001-03-27 |
Frank M. Richmond |
Spikeless connection and drip chamber with valve
|
US5540657A
(en)
*
|
1994-07-15 |
1996-07-30 |
Collagen Corporation |
Delivery device for injectable materials
|
DE19519279A1
(en)
*
|
1994-12-07 |
1996-08-22 |
Wolfgang Dr Med Wagner |
Measurement of, esp. glucose level, using suction cup
|
US5599302A
(en)
|
1995-01-09 |
1997-02-04 |
Medi-Ject Corporation |
Medical injection system and method, gas spring thereof and launching device using gas spring
|
DE29507987U1
(en)
*
|
1995-05-15 |
1996-09-19 |
Ferton Holding |
Ejection device for high pressure ejection of a liquid
|
US5893397A
(en)
*
|
1996-01-12 |
1999-04-13 |
Bioject Inc. |
Medication vial/syringe liquid-transfer apparatus
|
US5921967A
(en)
|
1996-02-29 |
1999-07-13 |
Medi-Ject Corporation |
Plunger for nozzle assembly
|
US5643211A
(en)
|
1996-02-29 |
1997-07-01 |
Medi-Ject Corporation |
Nozzle assembly having a frangible plunger
|
US5722953A
(en)
|
1996-02-29 |
1998-03-03 |
Medi-Ject Corporation |
Nozzle assembly for injection device
|
US5865795A
(en)
|
1996-02-29 |
1999-02-02 |
Medi-Ject Corporation |
Safety mechanism for injection devices
|
US5697917A
(en)
|
1996-02-29 |
1997-12-16 |
Medi-Ject Corporation |
Nozzle assembly with adjustable plunger travel gap
|
US5800388A
(en)
|
1996-02-29 |
1998-09-01 |
Medi-Ject Corporation |
Plunger/ram assembly adapted for a fluid injector
|
US5785688A
(en)
*
|
1996-05-07 |
1998-07-28 |
Ceramatec, Inc. |
Fluid delivery apparatus and method
|
AU727081B2
(en)
|
1996-07-01 |
2000-11-30 |
Pharmacia & Upjohn Ab |
Delivery device and method for its operation
|
US6458574B1
(en)
|
1996-09-12 |
2002-10-01 |
Transkaryotic Therapies, Inc. |
Treatment of a α-galactosidase a deficiency
|
US6106502A
(en)
*
|
1996-12-18 |
2000-08-22 |
Richmond; Frank M. |
IV sets with needleless fittings and valves
|
US5875976A
(en)
|
1996-12-24 |
1999-03-02 |
Medi-Ject Corporation |
Locking mechanism for nozzle assembly
|
US5993412A
(en)
*
|
1997-05-19 |
1999-11-30 |
Bioject, Inc. |
Injection apparatus
|
US5911703A
(en)
*
|
1997-05-22 |
1999-06-15 |
Avant Drug Delivery Systems, Inc. |
Two-stage fluid medicament jet injector
|
US5947928A
(en)
*
|
1997-06-19 |
1999-09-07 |
Mile Creek Capital, Llc |
Drug delivery system
|
US5964735A
(en)
*
|
1997-07-01 |
1999-10-12 |
Medisys Technologies, Inc. |
Fine needle aspiration safety syringe
|
EP0888790A1
(en)
*
|
1997-07-04 |
1999-01-07 |
PowderJect Research Limited |
Drug particle delivery device
|
US6569127B1
(en)
*
|
1997-07-18 |
2003-05-27 |
Liebel-Flarsheim Company |
Adapter and syringe for front-loading medical fluid injector
|
US6171276B1
(en)
|
1997-08-06 |
2001-01-09 |
Pharmacia & Upjohn Ab |
Automated delivery device and method for its operation
|
US6071272A
(en)
*
|
1997-10-28 |
2000-06-06 |
Hoffman; Alan S. |
Method for treating erectile dysfunctionality
|
US6610042B2
(en)
|
1997-12-05 |
2003-08-26 |
Felton Medical, Inc. |
Disposable unit-dose jet-injection syringe for pre-filled and/or transfilled liquid injectable medical drug or vaccine products and method thereof
|
US6541606B2
(en)
*
|
1997-12-31 |
2003-04-01 |
Altus Biologics Inc. |
Stabilized protein crystals formulations containing them and methods of making them
|
US5993418A
(en)
*
|
1998-02-24 |
1999-11-30 |
Medisys Technologies, Inc. |
Safety syringe
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
JP2002511396A
(en)
|
1998-04-14 |
2002-04-16 |
メルク エンド カムパニー インコーポレーテッド |
Needleless administration of polynucleotide preparations
|
ES2276524T3
(en)
*
|
1998-07-27 |
2007-06-16 |
Antares Pharma, Inc. |
INJECTION HELP PROBE FOR MEDICAL INJECTOR ASSEMBLY.
|
EP1100566A4
(en)
*
|
1998-07-27 |
2002-03-20 |
Medi Ject Corp |
Loading mechanism for medical injector assembly
|
GB9818110D0
(en)
*
|
1998-08-19 |
1998-10-14 |
Weston Medical Ltd |
Needleless injectors and other devices
|
WO2000012173A1
(en)
|
1998-08-31 |
2000-03-09 |
Johnson & Johnson Consumer Companies, Inc. |
Electrotransport device comprising blades
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
US6783509B1
(en)
|
1998-11-18 |
2004-08-31 |
Bioject Inc. |
Single-use needle-less hypodermic jet injection apparatus and method
|
US6383168B1
(en)
|
1998-12-08 |
2002-05-07 |
Bioject Medical Technologies Inc. |
Needleless syringe with prefilled cartridge
|
US6132395A
(en)
*
|
1998-12-08 |
2000-10-17 |
Bioject, Inc. |
Needleless syringe with prefilled cartridge
|
US6406455B1
(en)
*
|
1998-12-18 |
2002-06-18 |
Biovalve Technologies, Inc. |
Injection devices
|
DE19859137C1
(en)
*
|
1998-12-21 |
2000-05-18 |
Ferton Holding Sa |
High pressure medicinal injection unit includes piston advanced into pressure chamber by series of resilient impacts, forcing fluid out in series of impulses for precise low-volume dosing
|
US6849060B1
(en)
|
1999-01-29 |
2005-02-01 |
Powderject Research Limited |
Particle delivery device
|
US6328714B1
(en)
*
|
1999-01-29 |
2001-12-11 |
Powderject Research Limited |
Particle delivery device
|
DE60018726T2
(en)
|
1999-04-16 |
2006-04-13 |
Johnson & Johnson Consumer Companies, Inc. |
DEVICE FOR IONTOPHORETIC ADMINISTRATION OF MEDICAMENTS WITH INTERNAL SENSORS
|
US7060048B1
(en)
*
|
1999-04-16 |
2006-06-13 |
Powerject Research Limited |
Needleless syringe
|
AU4656000A
(en)
|
1999-04-22 |
2000-11-10 |
Gilbert Garitano |
Needleless permanent makeup and tattoo device
|
US6319230B1
(en)
|
1999-05-07 |
2001-11-20 |
Scimed Life Systems, Inc. |
Lateral needle injection apparatus and method
|
US6689103B1
(en)
|
1999-05-07 |
2004-02-10 |
Scimed Life System, Inc. |
Injection array apparatus and method
|
US7192713B1
(en)
|
1999-05-18 |
2007-03-20 |
President And Fellows Of Harvard College |
Stabilized compounds having secondary structure motifs
|
US7147633B2
(en)
*
|
1999-06-02 |
2006-12-12 |
Boston Scientific Scimed, Inc. |
Method and apparatus for treatment of atrial fibrillation
|
AU5595300A
(en)
*
|
1999-06-02 |
2000-12-18 |
Microheart, Inc. |
Devices and methods for delivering a drug
|
US6890553B1
(en)
|
1999-07-08 |
2005-05-10 |
Johnson & Johnson Consumer Companies, Inc. |
Exothermic topical delivery device
|
AU6076200A
(en)
|
1999-07-08 |
2001-01-30 |
Johnson & Johnson Consumer Companies, Inc. |
Exothermic bandage
|
US6319224B1
(en)
*
|
1999-08-20 |
2001-11-20 |
Bioject Medical Technologies Inc. |
Intradermal injection system for injecting DNA-based injectables into humans
|
US20050027239A1
(en)
*
|
1999-08-20 |
2005-02-03 |
Stout Richard R. |
Intradermal injection system for injecting DNA-based injectables into humans
|
WO2001013975A2
(en)
*
|
1999-08-20 |
2001-03-01 |
Bioject, Inc. |
Dna-based intramuscular injection system for humans
|
CA2589418A1
(en)
|
1999-08-24 |
2001-03-01 |
Medarex, Inc. |
Human ctla-4 antibodies and their uses
|
US7133717B2
(en)
*
|
1999-08-25 |
2006-11-07 |
Johnson & Johnson Consumer Companies, Inc. |
Tissue electroperforation for enhanced drug delivery and diagnostic sampling
|
US7113821B1
(en)
|
1999-08-25 |
2006-09-26 |
Johnson & Johnson Consumer Companies, Inc. |
Tissue electroperforation for enhanced drug delivery
|
EP1220697B1
(en)
|
1999-10-11 |
2004-12-29 |
Felton International, Inc. |
Universal anti-infectious protector for needleless injectors
|
US7074210B2
(en)
*
|
1999-10-11 |
2006-07-11 |
Felton International, Inc. |
Universal protector cap with auto-disable features for needle-free injectors
|
US20020193740A1
(en)
|
1999-10-14 |
2002-12-19 |
Alchas Paul G. |
Method of intradermally injecting substances
|
US6776776B2
(en)
*
|
1999-10-14 |
2004-08-17 |
Becton, Dickinson And Company |
Prefillable intradermal delivery device
|
US6494865B1
(en)
|
1999-10-14 |
2002-12-17 |
Becton Dickinson And Company |
Intradermal delivery device including a needle assembly
|
US6569123B2
(en)
|
1999-10-14 |
2003-05-27 |
Becton, Dickinson And Company |
Prefillable intradermal injector
|
US6569143B2
(en)
|
1999-10-14 |
2003-05-27 |
Becton, Dickinson And Company |
Method of intradermally injecting substances
|
US6843781B2
(en)
*
|
1999-10-14 |
2005-01-18 |
Becton, Dickinson And Company |
Intradermal needle
|
US7029457B2
(en)
*
|
1999-11-23 |
2006-04-18 |
Felton International, Inc. |
Jet injector with hand piece
|
CN1285389C
(en)
*
|
1999-11-23 |
2006-11-22 |
无针风险投资公司 |
Injector assembly with driving means and locking means
|
US6770054B1
(en)
|
1999-11-23 |
2004-08-03 |
Felton International, Inc. |
Injector assembly with driving means and locking means
|
US7887506B1
(en)
|
1999-11-23 |
2011-02-15 |
Pulse Needlefree Systems, Inc. |
Safety mechanism to prevent accidental patient injection and methods of same
|
US6344027B1
(en)
|
1999-12-08 |
2002-02-05 |
Scimed Life Systems, Inc. |
Needle-less injection apparatus and method
|
US6613026B1
(en)
*
|
1999-12-08 |
2003-09-02 |
Scimed Life Systems, Inc. |
Lateral needle-less injection apparatus and method
|
WO2001051109A1
(en)
*
|
2000-01-07 |
2001-07-19 |
Biovalve Technologies, Inc. |
Injection device
|
DE60143425D1
(en)
|
2000-02-23 |
2010-12-23 |
Smithkline Beecham Biolog |
NEW CONNECTIONS
|
FR2805749B1
(en)
*
|
2000-03-01 |
2002-05-17 |
Poudres & Explosifs Ste Nale |
NEEDLELESS SYRINGE AT TWO LEVELS OF INJECTION SPEED
|
US7137968B1
(en)
|
2000-03-13 |
2006-11-21 |
Nucryst Pharmaceuticals Corp. |
Transcutaneous medical device dressings and method of use
|
EP1265663B1
(en)
*
|
2000-03-23 |
2011-03-02 |
Antares Pharma, Inc. |
Single use disposable jet injector
|
US6719987B2
(en)
|
2000-04-17 |
2004-04-13 |
Nucryst Pharmaceuticals Corp. |
Antimicrobial bioabsorbable materials
|
FR2807946B1
(en)
|
2000-04-19 |
2002-06-07 |
Poudres & Explosifs Ste Nale |
NEEDLELESS SYRINGE OPERATING WITH A TWO-COMPOSITION PYROTECHNIC LOAD
|
US6716190B1
(en)
*
|
2000-04-19 |
2004-04-06 |
Scimed Life Systems, Inc. |
Device and methods for the delivery and injection of therapeutic and diagnostic agents to a target site within a body
|
US7404815B2
(en)
*
|
2000-05-01 |
2008-07-29 |
Lifescan, Inc. |
Tissue ablation by shear force for sampling biological fluids and delivering active agents
|
US6689101B2
(en)
*
|
2000-05-22 |
2004-02-10 |
Pharmacia Ab |
Medical arrangement
|
US6645169B1
(en)
*
|
2000-06-08 |
2003-11-11 |
Avant Drug Delivery Systems, Inc. |
Air-in-tip jet injector
|
US6406456B1
(en)
|
2000-06-08 |
2002-06-18 |
Avant Drug Delivery Systems, Inc. |
Jet injector
|
DE10029325A1
(en)
*
|
2000-06-20 |
2002-01-03 |
Peter Lell |
Needle-free injection device with pyrotechnic drive
|
JP2004513615A
(en)
|
2000-06-28 |
2004-05-13 |
コリクサ コーポレイション |
Compositions and methods for treatment and diagnosis of lung cancer
|
US20030185901A1
(en)
|
2000-07-27 |
2003-10-02 |
Burrell Robert E. |
Methods of treating conditions with a metal-containing material
|
US20030180379A1
(en)
*
|
2000-07-27 |
2003-09-25 |
Burrell Robert E. |
Solutions and aerosols of metal-containing compounds
|
US7427416B2
(en)
*
|
2000-07-27 |
2008-09-23 |
Nucryst Pharmaceuticals Corp. |
Methods of treating conditions using metal-containing materials
|
AU2001278322B2
(en)
|
2000-07-27 |
2005-12-22 |
Smith & Nephew (Overseas) Limited |
Treatment of hyperproliferative skin disorders and diseases
|
US6989157B2
(en)
*
|
2000-07-27 |
2006-01-24 |
Nucryst Pharmaceuticals Corp. |
Dry powders of metal-containing compounds
|
US7255881B2
(en)
*
|
2000-07-27 |
2007-08-14 |
Nucryst Pharmaceuticals Corp. |
Metal-containing materials
|
US20030206966A1
(en)
*
|
2000-07-27 |
2003-11-06 |
Burrell Robert E. |
Methods of inducing apoptosis and modulating metalloproteinases
|
US7008647B2
(en)
*
|
2001-04-23 |
2006-03-07 |
Nucryst Pharmaceuticals Corp. |
Treatment of acne
|
US7001617B2
(en)
|
2001-04-23 |
2006-02-21 |
Nueryst Pharmaceuticals Corp. |
Method of induction of apoptosis and inhibition of matrix metalloproteinases using antimicrobial metals
|
US20040191329A1
(en)
*
|
2000-07-27 |
2004-09-30 |
Burrell Robert E. |
Compositions and methods of metal-containing materials
|
GB0022742D0
(en)
|
2000-09-15 |
2000-11-01 |
Smithkline Beecham Biolog |
Vaccine
|
CA2324045A1
(en)
*
|
2000-10-20 |
2002-04-20 |
Universite De Sherbrooke |
No-needle syringe for the subcutaneous injection of medicated powders
|
FR2815544B1
(en)
*
|
2000-10-23 |
2003-02-14 |
Poudres & Explosifs Ste Nale |
SAFETY NEEDLE SYRINGE WITH COMPACT ARCHITECTURE
|
US6652483B2
(en)
*
|
2000-11-07 |
2003-11-25 |
Avant Drug Delivery Systems, Inc. |
Needleless jet injector system with separate drug reservoir
|
US6626863B1
(en)
|
2000-11-22 |
2003-09-30 |
Nusaf, L.L.C. |
Safety syringe
|
EP1339442A4
(en)
*
|
2000-11-30 |
2006-12-27 |
Biovalve Technologies Inc |
Injection systems
|
GB0100756D0
(en)
|
2001-01-11 |
2001-02-21 |
Powderject Res Ltd |
Needleless syringe
|
WO2002056947A1
(en)
*
|
2001-01-18 |
2002-07-25 |
Medrad, Inc. |
Syringe interfaces and adapters for use with medical injectors
|
US6758837B2
(en)
*
|
2001-02-08 |
2004-07-06 |
Pharmacia Ab |
Liquid delivery device and method of use thereof
|
JP5208347B2
(en)
|
2001-02-23 |
2013-06-12 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
New vaccine
|
US6645170B2
(en)
*
|
2001-03-05 |
2003-11-11 |
Bioject Medical Technologies, Inc. |
Simplified disposable needle-free injection apparatus and method
|
US6471669B2
(en)
|
2001-03-05 |
2002-10-29 |
Bioject Medical Technologies Inc. |
Disposable needle-free injection apparatus and method
|
US20020139088A1
(en)
|
2001-03-08 |
2002-10-03 |
Archie Woodworth |
Polymeric syringe body and stopper
|
US20020172615A1
(en)
*
|
2001-03-08 |
2002-11-21 |
Archie Woodworth |
Apparatus for and method of manufacturing a prefilled sterile container
|
US6500239B2
(en)
|
2001-03-14 |
2002-12-31 |
Penjet Corporation |
System and method for removing dissolved gas from a solution
|
ZA200200808B
(en)
*
|
2001-03-22 |
2002-08-12 |
Roche Diagnostics Gmbh |
Needleless hypodermic injection system, application device and medication cartridge therefor.
|
GB0109297D0
(en)
|
2001-04-12 |
2001-05-30 |
Glaxosmithkline Biolog Sa |
Vaccine
|
US7795218B2
(en)
|
2001-04-12 |
2010-09-14 |
Bioaxone Therapeutique Inc. |
ADP-ribosyl transferase fusion variant proteins
|
US20050192530A1
(en)
*
|
2001-04-13 |
2005-09-01 |
Penjet Corporation |
Method and apparatus for needle-less injection with a degassed fluid
|
US6613010B2
(en)
|
2001-04-13 |
2003-09-02 |
Penjet Corporation |
Modular gas-pressured needle-less injector
|
ATE322274T1
(en)
|
2001-04-23 |
2006-04-15 |
Nucryst Pharm Corp |
MEDICINAL PRODUCTS OR PLASTERS CONTAINING A METAL SUCH AS SILVER GOLD, PLATINUM OR PALLADIUM AS AN ANTIMICROBIAL ACTIVE AND THEIR USE IN THE TREATMENT OF SKIN INFLAMMATION
|
US6755220B2
(en)
|
2001-04-27 |
2004-06-29 |
Penjet Corporation |
Method and apparatus for filling or refilling a needle-less injector
|
JP2005504513A
(en)
|
2001-05-09 |
2005-02-17 |
コリクサ コーポレイション |
Compositions and methods for treatment and diagnosis of prostate cancer
|
MY134424A
(en)
|
2001-05-30 |
2007-12-31 |
Saechsisches Serumwerk |
Stable influenza virus preparations with low or no amount of thiomersal
|
US20100221284A1
(en)
|
2001-05-30 |
2010-09-02 |
Saech-Sisches Serumwerk Dresden |
Novel vaccine composition
|
US6648850B2
(en)
*
|
2001-06-08 |
2003-11-18 |
Bioject, Inc. |
Durable needle-less jet injector apparatus and method
|
US20060018877A1
(en)
*
|
2001-06-29 |
2006-01-26 |
Mikszta John A |
Intradermal delivery of vacccines and therapeutic agents
|
JP2004531578A
(en)
*
|
2001-06-29 |
2004-10-14 |
ベクトン・ディキンソン・アンド・カンパニー |
Intradermal delivery of vaccines and gene therapeutics by microcannula
|
US7544188B2
(en)
*
|
2001-07-19 |
2009-06-09 |
Intelliject, Inc. |
Medical injector
|
US8440791B2
(en)
*
|
2001-09-06 |
2013-05-14 |
Mgp Biotechnologies, Llc |
Thimerosal removal device
|
US7767872B2
(en)
*
|
2001-09-06 |
2010-08-03 |
Mpg Biotechnologies, Llc |
Thimerosal removal device
|
US6669664B2
(en)
|
2001-09-07 |
2003-12-30 |
Avant Drug Delivery Systems, Inc. |
Vacuum control cycle for jet injector
|
US20060068405A1
(en)
*
|
2004-01-27 |
2006-03-30 |
Alex Diber |
Methods and systems for annotating biomolecular sequences
|
US20070015721A1
(en)
*
|
2001-09-20 |
2007-01-18 |
Andrew Beaton |
Hiv-gag codon-optimised dna vaccines
|
US6824526B2
(en)
|
2001-10-22 |
2004-11-30 |
Penjet Corporation |
Engine and diffuser for use with a needle-less injector
|
GB0125506D0
(en)
|
2001-10-24 |
2001-12-12 |
Weston Medical Ltd |
Needle free injection method and apparatus
|
NZ532146A
(en)
*
|
2001-11-09 |
2006-07-28 |
Alza Corp |
Collapsible syringe cartridge
|
US6607510B2
(en)
|
2001-11-09 |
2003-08-19 |
Bioject Medical Technologies Inc. |
Disposable needle-free injection apparatus and method
|
SI2221076T1
(en)
*
|
2001-11-09 |
2013-06-28 |
Alza Corporation |
Pneumatic powered autoinjector
|
TWI222370B
(en)
*
|
2001-12-14 |
2004-10-21 |
Roche Diagnostics Gmbh |
Needleless hypodermic injection device
|
ES2405790T3
(en)
|
2001-12-17 |
2013-06-03 |
Corixa Corporation |
Compositions and methods for therapy and diagnosis of inflammatory bowel disease
|
WO2003074102A2
(en)
*
|
2002-03-04 |
2003-09-12 |
Nano Pass Technologies Ltd. |
Devices and methods for transporting fluid across a biological barrier
|
US6912417B1
(en)
*
|
2002-04-05 |
2005-06-28 |
Ichor Medical Systmes, Inc. |
Method and apparatus for delivery of therapeutic agents
|
ATE545866T1
(en)
|
2002-04-12 |
2012-03-15 |
Schering Corp |
LIGANDS OF G-PROTEIN-COUPLED RECEPTORS AND METHODS
|
ATE514430T1
(en)
|
2002-04-25 |
2011-07-15 |
Shire Human Genetic Therapies |
TREATMENT OF ALPHA-GALACTOSIDASE A DEFICIENCY
|
NZ554740A
(en)
|
2002-05-24 |
2009-01-31 |
Schering Corp |
Neutralizing human anti-IGFR antibody
|
US6676630B2
(en)
|
2002-06-04 |
2004-01-13 |
Bioject Medical Technologies, Inc. |
Needle-free injection system
|
US7238167B2
(en)
*
|
2002-06-04 |
2007-07-03 |
Bioject Inc. |
Needle-free injection system
|
US7156823B2
(en)
*
|
2002-06-04 |
2007-01-02 |
Bioject Inc. |
High workload needle-free injection system
|
US20040132058A1
(en)
|
2002-07-19 |
2004-07-08 |
Schering Corporation |
NPC1L1 (NPC3) and methods of use thereof
|
US6883222B2
(en)
*
|
2002-10-16 |
2005-04-26 |
Bioject Inc. |
Drug cartridge assembly and method of manufacture
|
NZ568769A
(en)
|
2002-10-17 |
2010-04-30 |
Genmab As |
Human monoclonal antibodies against CD20
|
JP2006509738A
(en)
*
|
2002-10-22 |
2006-03-23 |
ニュクリスト ファーマシューティカルズ コーポレーション |
Prophylactic treatment
|
DE10254601A1
(en)
|
2002-11-22 |
2004-06-03 |
Ganymed Pharmaceuticals Ag |
Gene products differentially expressed in tumors and their use
|
EP1572271A1
(en)
|
2002-11-25 |
2005-09-14 |
Tecpharma Licensing AG |
Auto-injector comprising a resettable releasing safety device
|
WO2004062599A2
(en)
|
2003-01-06 |
2004-07-29 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
EP1587907B1
(en)
|
2003-01-07 |
2011-03-02 |
Dyax Corporation |
Kunitz domain library
|
DK2441467T3
(en)
|
2003-01-31 |
2015-08-31 |
Sinai School Medicine |
Combination therapy for the treatment of protein deficiency disorders
|
US6935384B2
(en)
*
|
2003-02-19 |
2005-08-30 |
Bioject Inc. |
Needle-free injection system
|
FR2852517B1
(en)
*
|
2003-03-21 |
2005-11-11 |
|
INJECTION DEVICE WITHOUT NEEDLE WITH PYROTECHNIC CARTRIDGE AND METHOD FOR ASSEMBLING SUCH A DEVICE
|
US20060184101A1
(en)
*
|
2003-04-21 |
2006-08-17 |
Ravi Srinivasan |
Microjet devices and methods for drug delivery
|
EP1620147A4
(en)
*
|
2003-04-21 |
2008-06-11 |
Corium Internat Inc |
Apparatus and methods for repetitive microjet drug delivery
|
ATE517920T1
(en)
|
2003-04-23 |
2011-08-15 |
Medarex Inc |
HUMANIZED ANTIBODIES AGAINST INTERFERON ALPHA RECEPTOR-1 (IFNAR-1)
|
WO2004110533A1
(en)
*
|
2003-05-09 |
2004-12-23 |
Anges Mg, Inc. |
Needleless syringe having medical agent accommodated therein
|
AU2004272972A1
(en)
|
2003-05-22 |
2005-03-24 |
Fraunhofer Usa, Inc. |
Recombinant carrier molecule for expression, delivery and purification of target polypeptides
|
WO2005034949A1
(en)
*
|
2003-09-09 |
2005-04-21 |
University Of Florida |
Desferrithiocin derivatives and their use as iron chelators
|
IL157981A
(en)
|
2003-09-17 |
2014-01-30 |
Elcam Medical Agricultural Cooperative Ass Ltd |
Auto-injector
|
GB0325836D0
(en)
*
|
2003-11-05 |
2003-12-10 |
Celltech R&D Ltd |
Biological products
|
EP1687026B1
(en)
|
2003-11-21 |
2008-05-14 |
UCB Pharma, S.A. |
Method for the treatment of multiple sclerosis by inhibiting il-17 activity
|
EP1685865A4
(en)
*
|
2003-11-21 |
2009-12-30 |
Zhongshan Botai Pharmaceutic I |
A syringe for powder medicament premixing
|
CN102838675B
(en)
|
2003-12-10 |
2014-07-30 |
梅达雷克斯有限责任公司 |
Ip-10 antibodies and their uses
|
US7741449B2
(en)
|
2003-12-10 |
2010-06-22 |
Medarex, Inc. |
Anti-interferon alpha antibodies
|
CN1997423B
(en)
|
2004-03-08 |
2012-10-03 |
艾科医疗系统公司 |
Improved apparatus for electrically mediated delivery of therapeutic agents
|
IL160891A0
(en)
|
2004-03-16 |
2004-08-31 |
|
Auto-mix needle
|
DE102004024617A1
(en)
|
2004-05-18 |
2005-12-29 |
Ganymed Pharmaceuticals Ag |
Differentially expressed in tumors gene products and their use
|
AU2005244942A1
(en)
*
|
2004-05-19 |
2005-12-01 |
Wyeth |
Modulation of immunoglobulin production and atopic disorders
|
US7717874B2
(en)
*
|
2004-05-28 |
2010-05-18 |
Bioject, Inc. |
Needle-free injection system
|
CA2570823C
(en)
|
2004-06-21 |
2015-02-24 |
Medarex, Inc. |
Interferon alpha receptor 1 antibodies and their uses
|
EP1807451A2
(en)
|
2004-08-03 |
2007-07-18 |
Dyax Corporation |
Hk1-binding proteins
|
GB0417852D0
(en)
|
2004-08-11 |
2004-09-15 |
Biotica Tech Ltd |
Production of polyketides and other natural products
|
US20060040895A1
(en)
*
|
2004-08-19 |
2006-02-23 |
Kipling Thacker |
Aesthetic use of hyaluronan
|
CA2478458A1
(en)
*
|
2004-08-20 |
2006-02-20 |
Michael Panzara |
Treatment of pediatric multiple sclerosis
|
KR101508563B1
(en)
|
2004-09-22 |
2015-04-07 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
Immunogenic composition for use in vaccination against staphylococcei
|
WO2007001448A2
(en)
*
|
2004-11-04 |
2007-01-04 |
Massachusetts Institute Of Technology |
Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
|
EP1817590A2
(en)
|
2004-11-08 |
2007-08-15 |
Schering Corporation |
Tumor association of mdl-1 and methods
|
EP1824976A4
(en)
|
2004-11-12 |
2008-07-09 |
Univ British Columbia |
Antimicrobial peptides
|
EP2808033A1
(en)
|
2004-11-19 |
2014-12-03 |
Biogen Idec MA Inc. |
Treatment for multiple sclerosis
|
US7648482B2
(en)
|
2004-11-22 |
2010-01-19 |
Intelliject, Inc. |
Devices, systems, and methods for medicament delivery
|
CA2891057C
(en)
|
2004-11-22 |
2018-11-13 |
Kaleo, Inc. |
Medicament delivery apparatus and movable indicator
|
US10737028B2
(en)
|
2004-11-22 |
2020-08-11 |
Kaleo, Inc. |
Devices, systems and methods for medicament delivery
|
US11590286B2
(en)
|
2004-11-22 |
2023-02-28 |
Kaleo, Inc. |
Devices, systems and methods for medicament delivery
|
US7947017B2
(en)
|
2004-11-22 |
2011-05-24 |
Intelliject, Inc. |
Devices, systems and methods for medicament delivery
|
US7648483B2
(en)
|
2004-11-22 |
2010-01-19 |
Intelliject, Inc. |
Devices, systems and methods for medicament delivery
|
WO2006058426A1
(en)
*
|
2004-12-01 |
2006-06-08 |
Wlt Distributors Inc. |
Needle-free injector
|
ES2356830T3
(en)
|
2004-12-03 |
2011-04-13 |
Schering Corporation |
BIOMARCATORS FOR PRESELECTION OF PATIENTS FOR ANTI-IGF-1R THERAPY.
|
US20090169477A1
(en)
*
|
2004-12-03 |
2009-07-02 |
Michael Panzara |
Delaying or preventing onset of multiple sclerosis
|
US7351226B1
(en)
*
|
2004-12-07 |
2008-04-01 |
Glenn Herskowitz |
Medical infusion pump
|
AU2005325716A1
(en)
*
|
2005-01-25 |
2006-08-03 |
Sky Genetics, Inc. |
Nucleic acids for apoptosis of cancer cells
|
US20060183893A1
(en)
*
|
2005-01-25 |
2006-08-17 |
North Don A |
Nucleic acids for apoptosis of cancer cells
|
JP4948422B2
(en)
|
2005-02-01 |
2012-06-06 |
インテリジェクト,インコーポレイテッド |
Drug delivery apparatus, system and method
|
US7731686B2
(en)
|
2005-02-01 |
2010-06-08 |
Intelliject, Inc. |
Devices, systems and methods for medicament delivery
|
US9022980B2
(en)
|
2005-02-01 |
2015-05-05 |
Kaleo, Inc. |
Medical injector simulation device
|
US8361026B2
(en)
|
2005-02-01 |
2013-01-29 |
Intelliject, Inc. |
Apparatus and methods for self-administration of vaccines and other medicaments
|
US8231573B2
(en)
|
2005-02-01 |
2012-07-31 |
Intelliject, Inc. |
Medicament delivery device having an electronic circuit system
|
US8206360B2
(en)
|
2005-02-01 |
2012-06-26 |
Intelliject, Inc. |
Devices, systems and methods for medicament delivery
|
DK2332408T3
(en)
|
2005-02-17 |
2013-12-02 |
Biogen Idec Inc |
Treatment of neurological diseases
|
EP1848745B1
(en)
|
2005-02-18 |
2014-07-09 |
Medarex, L.L.C. |
Monoclonal antibodies against cd30 lacking in fucosyl residues
|
GB0504994D0
(en)
|
2005-03-11 |
2005-04-20 |
Biotica Tech Ltd |
Novel compounds
|
US20100061994A1
(en)
*
|
2005-03-11 |
2010-03-11 |
Rose Mary Sheridan |
Medical uses of 39-desmethoxyrapamycin and analogues thereof
|
EP2551282A3
(en)
|
2005-03-23 |
2013-02-13 |
Genmab A/S |
Antibodies against CD38 for treatment of multiple myeloma
|
CA2601022C
(en)
|
2005-03-23 |
2023-03-07 |
Glaxosmithkline Biologicals S.A. |
Use of an influenza virus an oil-in-water emulsion adjuvant to induce cd4 t-cell and/or improved b-memory cell response
|
KR20140068234A
(en)
|
2005-03-31 |
2014-06-05 |
더 제너럴 하스피탈 코포레이션 |
Monitoring and modulating hgf/hgfr activity
|
TR201910900T4
(en)
|
2005-04-04 |
2019-08-21 |
Univ Florida |
Desferritiokine polyether analogs.
|
DK2161336T4
(en)
|
2005-05-09 |
2017-04-24 |
Ono Pharmaceutical Co |
Human monoclonal antibodies for programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapies
|
EP1896083B1
(en)
|
2005-05-17 |
2016-03-02 |
Amicus Therapeutics, Inc. |
A method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives
|
SG162728A1
(en)
|
2005-05-27 |
2010-07-29 |
Biogen Idec Inc |
Tweak binding antibodies
|
US20060271014A1
(en)
*
|
2005-05-31 |
2006-11-30 |
Mallinckrodt Inc. |
Heat retention device for a syringe and methods of use
|
US20070118093A1
(en)
*
|
2005-06-20 |
2007-05-24 |
Von Muhlen Marcio G |
High-speed jet devices for drug delivery
|
AU2006265108C1
(en)
|
2005-07-01 |
2013-01-17 |
E. R. Squibb & Sons, L.L.C. |
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
|
US20100119525A1
(en)
*
|
2005-08-01 |
2010-05-13 |
Mount Sinai Schoool Of Medicine Of New York University |
Method for extending longevity using npc1l1 antagonists
|
BRPI0614475B8
(en)
*
|
2005-08-03 |
2021-05-25 |
Fraunhofer Usa Inc |
polypeptide, antibody, nucleic acid, vectors, host cell, antibody composition and production processes
|
US8591457B2
(en)
*
|
2005-08-10 |
2013-11-26 |
Alza Corporation |
Method for making a needle-free jet injection drug delivery device
|
EP1762575A1
(en)
|
2005-09-12 |
2007-03-14 |
Ganymed Pharmaceuticals AG |
Identification of tumor-associated antigens for diagnosis and therapy
|
EP1934261B1
(en)
|
2005-09-26 |
2014-10-29 |
Medarex, L.L.C. |
Human monoclonal antibodies to cd70
|
JP5006330B2
(en)
|
2005-10-21 |
2012-08-22 |
ノバルティス アーゲー |
Human antibodies against IL13 and therapeutic uses
|
US20070099246A1
(en)
*
|
2005-11-03 |
2007-05-03 |
Sandy John D |
Antibodies, assays and kits to quantitate cartilage destruction
|
WO2007061896A1
(en)
|
2005-11-17 |
2007-05-31 |
Zogenix, Inc. |
Delivery of viscous formulations by needle-free injection
|
EP1790664A1
(en)
|
2005-11-24 |
2007-05-30 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies against claudin-18 for treatment of cancer
|
JP2009518080A
(en)
*
|
2005-12-05 |
2009-05-07 |
中山博泰薬械有限公司 |
Automatic syringe
|
CN103204931B
(en)
|
2005-12-08 |
2016-08-03 |
米德列斯公司 |
The human monoclonal antibodies of anti-fucosyl-GM 1 and the method for use anti-fucosyl-GM 1 antibody
|
TWI457133B
(en)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
Novel composition
|
WO2007070682A2
(en)
*
|
2005-12-15 |
2007-06-21 |
Massachusetts Institute Of Technology |
System for screening particles
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
CA2816182C
(en)
|
2005-12-22 |
2018-02-20 |
Glaxosmithkline Biologicals S.A. |
Pneumococcal polysaccharide conjugate vaccine
|
CA2636424A1
(en)
|
2006-01-09 |
2007-10-25 |
The Regents Of The University Of California |
Immunostimulatory combinations of tnfrsf, tlr, nlr, rhr, purinergic receptor, and cytokine receptor agonists for vaccines and tumor immunotherapy
|
US20070166774A1
(en)
*
|
2006-01-17 |
2007-07-19 |
Groman Ernest V |
Functional immunoassay
|
EP1986612B1
(en)
|
2006-02-07 |
2012-09-12 |
Shire Human Genetic Therapies, Inc. |
Stabilized composition of glucocerebrosidase
|
WO2007092637A2
(en)
*
|
2006-02-09 |
2007-08-16 |
Deka Products Limited Partnership |
Patch-sized fluid delivery systems and methods
|
US8277816B2
(en)
*
|
2006-02-13 |
2012-10-02 |
Fraunhofer Usa, Inc. |
Bacillus anthracis antigens, vaccine compositions, and related methods
|
CA2642056A1
(en)
*
|
2006-02-13 |
2007-08-23 |
Fraunhofer Usa, Inc. |
Hpv antigens, vaccine compositions, and related methods
|
KR20080106433A
(en)
*
|
2006-02-13 |
2008-12-05 |
프라운호퍼 유에스에이, 인코포레이티드 |
Influenza antigens, vaccine compositions, and related methods
|
SG169997A1
(en)
*
|
2006-02-17 |
2011-04-29 |
Alan L Buchman |
Catheter cleaning devices
|
EP1998684A4
(en)
*
|
2006-03-10 |
2014-09-17 |
Massachusetts Inst Technology |
Triggered self-assembly conjugates and nanosystems
|
WO2007111806A2
(en)
*
|
2006-03-23 |
2007-10-04 |
Massachusetts Eye And Ear Infirmary |
Cyclopentane heptanoic acid compounds for reducing body fat
|
US20080045471A1
(en)
*
|
2006-03-27 |
2008-02-21 |
North Don A |
Nucleic Acids For Apoptosis Of Cancer Cells
|
US20100021503A1
(en)
|
2006-03-30 |
2010-01-28 |
Glaxosmithkline Biologicals S.A. |
Immunogenic composition
|
WO2008105773A2
(en)
|
2006-03-31 |
2008-09-04 |
Massachusetts Institute Of Technology |
System for targeted delivery of therapeutic agents
|
US20090325944A1
(en)
*
|
2006-04-12 |
2009-12-31 |
Suzanne Walker Kahne |
Methods and Compositions for Modulating Glycosylation
|
MX2008013535A
(en)
*
|
2006-04-21 |
2008-10-29 |
Amgen Inc |
Buffering agents for biopharmaceutical formulations.
|
US20070258941A1
(en)
*
|
2006-05-02 |
2007-11-08 |
Pfister Brian E |
Methods and compositions for remediation of disc herniation by modifying structure
|
CA2652280C
(en)
|
2006-05-15 |
2014-01-28 |
Massachusetts Institute Of Technology |
Polymers for functional particles
|
US20110052697A1
(en)
*
|
2006-05-17 |
2011-03-03 |
Gwangju Institute Of Science & Technology |
Aptamer-Directed Drug Delivery
|
DK2034830T3
(en)
|
2006-05-25 |
2014-10-27 |
Biogen Idec Inc |
ANTI-VLA-1 ANTIBODY FOR TREATMENT OF CASES
|
ES2570334T3
(en)
|
2006-06-02 |
2016-05-17 |
Harvard College |
Surface protein remodeling
|
WO2007150030A2
(en)
|
2006-06-23 |
2007-12-27 |
Massachusetts Institute Of Technology |
Microfluidic synthesis of organic nanoparticles
|
ES2427924T3
(en)
|
2006-06-30 |
2013-11-04 |
Merck Sharp & Dohme Corp. |
IGFBP2 biomarker
|
CA2656620C
(en)
|
2006-07-04 |
2018-03-13 |
Genmab A/S |
Cd20 binding molecules for the treatment of copd
|
CN105727276A
(en)
|
2006-07-17 |
2016-07-06 |
葛兰素史密丝克莱恩生物有限公司 |
Influenza vaccine
|
US20080033347A1
(en)
*
|
2006-08-03 |
2008-02-07 |
Becton, Dickinson And Company |
Detachable needle syringe having reduced dead space
|
US7618396B2
(en)
*
|
2006-08-09 |
2009-11-17 |
Avant Medical Corp. |
Injection system with hidden needles
|
US9115358B2
(en)
*
|
2006-08-11 |
2015-08-25 |
President And Fellows Of Harvard College |
Moenomycin biosynthesis-related compositions and methods of use thereof
|
TW200817437A
(en)
|
2006-08-11 |
2008-04-16 |
Medarex Inc |
Monoclonal antibodies against stromal cell derived factor-1 (SDF-1)
|
JP2010500880A
(en)
*
|
2006-08-14 |
2010-01-14 |
マサチューセッツ・インスティテュート・オブ・テクノロジー |
Hemagglutinin polypeptide and reagents and methods related to hemagglutinin polypeptide
|
US20090269342A1
(en)
*
|
2006-08-14 |
2009-10-29 |
Massachusetts Institute Of Technology |
Hemagglutinin Polypeptides, and Reagents and Methods Relating Thereto
|
EP2074144A4
(en)
|
2006-09-05 |
2011-03-16 |
Medarex Inc |
Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
|
US7942845B2
(en)
*
|
2006-09-19 |
2011-05-17 |
Bioject, Inc. |
Needle-free injector and process for providing serial injections
|
PL2486941T3
(en)
|
2006-10-02 |
2017-08-31 |
E. R. Squibb & Sons, L.L.C. |
Human antibodies that bind CXCR4 and uses thereof
|
US7547293B2
(en)
|
2006-10-06 |
2009-06-16 |
Bioject, Inc. |
Triggering mechanism for needle-free injector
|
AU2007307107B2
(en)
*
|
2006-10-06 |
2011-11-03 |
Amgen Inc. |
Stable antibody formulations
|
JO3598B1
(en)
*
|
2006-10-10 |
2020-07-05 |
Infinity Discovery Inc |
Boronic acids and esters as inhibitors of fatty acid amide hydrolase
|
BRPI0717219B8
(en)
|
2006-10-12 |
2021-05-25 |
Glaxosmithkline Biologicals Sa |
immunogenic composition, and, use of an immunogenic composition
|
EP2433648A3
(en)
|
2006-10-12 |
2012-04-04 |
GlaxoSmithKline Biologicals S.A. |
Vaccine comprising an oil in water emulsion adjuvant
|
US8613925B2
(en)
|
2006-10-19 |
2013-12-24 |
Csl Limited |
Anti-IL-13Rα1 antibodies and their uses thereof
|
TW200833357A
(en)
*
|
2006-10-20 |
2008-08-16 |
Amgen Inc |
Stable polypeptide formulations
|
EP2073833A2
(en)
|
2006-10-20 |
2009-07-01 |
Biogen Idec MA Inc. |
Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor
|
US8618248B2
(en)
|
2006-10-31 |
2013-12-31 |
President And Fellows Of Harvard College |
Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
|
US20090124996A1
(en)
*
|
2006-11-03 |
2009-05-14 |
Scott Heneveld |
Apparatus and methods for injecting high viscosity dermal fillers
|
MX2009005189A
(en)
|
2006-11-15 |
2009-06-30 |
Medarex Inc |
Human monoclonal antibodies to btla and methods of use.
|
US20100303723A1
(en)
*
|
2006-11-20 |
2010-12-02 |
Massachusetts Institute Of Technology |
Drug delivery systems using fc fragments
|
TWI447124B
(en)
|
2006-12-01 |
2014-08-01 |
Medarex Llc |
Human antibodies that bind cd22 and uses thereof
|
US20100150994A1
(en)
|
2006-12-01 |
2010-06-17 |
Anterios, Inc. |
Amphiphilic entity nanoparticles
|
AU2007333225B2
(en)
*
|
2006-12-08 |
2014-06-12 |
Massachusetts Institute Of Technology |
Delivery of nanoparticles and/or agents to cells
|
CL2007003622A1
(en)
|
2006-12-13 |
2009-08-07 |
Medarex Inc |
Human anti-cd19 monoclonal antibody; composition comprising it; and tumor cell growth inhibition method.
|
KR20090088946A
(en)
|
2006-12-14 |
2009-08-20 |
메다렉스, 인코포레이티드 |
Human antibodies that bind cd70 and uses thereof
|
EP2129401B8
(en)
*
|
2006-12-21 |
2020-01-15 |
Amgen Inc. |
Stable buffered formulations containing polypeptides
|
TWI618544B
(en)
|
2006-12-26 |
2018-03-21 |
藍瑟斯醫學影像公司 |
Ligands for imaging cardiac innervation
|
WO2008083209A2
(en)
*
|
2006-12-29 |
2008-07-10 |
Amir Genosar |
Hypodermic drug delivery reservoir and apparatus
|
WO2008091838A2
(en)
|
2007-01-22 |
2008-07-31 |
Intelliject, Inc. |
Medical injector with compliance tracking and monitoring
|
PT2118123E
(en)
|
2007-01-31 |
2016-02-10 |
Harvard College |
Stabilized p53 peptides and uses thereof
|
WO2008098165A2
(en)
*
|
2007-02-09 |
2008-08-14 |
Massachusetts Institute Of Technology |
Oscillating cell culture bioreactor
|
SG178789A1
(en)
|
2007-02-16 |
2012-03-29 |
Merrimack Pharmaceuticals Inc |
Antibodies against erbb3 and uses thereof
|
WO2008103997A2
(en)
*
|
2007-02-23 |
2008-08-28 |
Bioject Inc. |
Needle-free injection devices and drug delivery systems therefor
|
EP1970384A1
(en)
*
|
2007-03-14 |
2008-09-17 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies for treatment of cancer
|
CA2680592C
(en)
|
2007-03-15 |
2016-07-05 |
University Of Florida Research Foundation, Inc. |
Desferrithiocin polyether analogues and uses thereof in treating pathological conditions
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
CA2680237C
(en)
|
2007-03-27 |
2018-11-06 |
Sea Lane Biotechnologies, Llc |
Constructs and libraries comprising antibody surrogate light chain sequences
|
EP2508531B1
(en)
|
2007-03-28 |
2016-10-19 |
President and Fellows of Harvard College |
Stitched polypeptides
|
EP2144600A4
(en)
|
2007-04-04 |
2011-03-16 |
Massachusetts Inst Technology |
Poly (amino acid) targeting moieties
|
WO2008124634A1
(en)
|
2007-04-04 |
2008-10-16 |
Massachusetts Institute Of Technology |
Polymer-encapsulated reverse micelles
|
CA2685558A1
(en)
*
|
2007-04-28 |
2008-11-06 |
Fraunhofer Usa, Inc. |
Trypanosoma antigens, vaccine compositions, and related methods
|
GB0708758D0
(en)
*
|
2007-05-04 |
2007-06-13 |
Powderject Res Ltd |
Particle cassettes and process thereof
|
EP2167480A2
(en)
|
2007-05-23 |
2010-03-31 |
Vical Incorporated |
Cationic lipids compositions and methods for enhancing immune responses to vaccines
|
EP1997832A1
(en)
|
2007-05-29 |
2008-12-03 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies against Claudin-18 for treatment of cancer
|
CN103694351A
(en)
|
2007-06-05 |
2014-04-02 |
耶鲁大学 |
Inhibitors of receptor tyrosine kinases and methods of use thereof
|
DK2175881T3
(en)
*
|
2007-06-14 |
2012-10-22 |
Crucell Switzerland Ag |
Intradermal influenza vaccine
|
PT2170390T
(en)
|
2007-06-14 |
2019-02-12 |
Biogen Ma Inc |
Natalizumab antibody formulations
|
US8524444B2
(en)
|
2007-06-15 |
2013-09-03 |
President And Fellows Of Harvard College |
Methods and compositions for detections and modulating O-glycosylation
|
KR101579947B1
(en)
|
2007-06-26 |
2015-12-28 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
|
CA2692933C
(en)
*
|
2007-07-11 |
2016-10-18 |
Fraunhofer Usa, Inc. |
Yersinia pestis antigens, vaccine compositions, and related methods
|
DE102007034871A1
(en)
*
|
2007-07-24 |
2009-01-29 |
Lts Lohmann Therapie-Systeme Ag |
Disposable injector with manually operated piston
|
US9693539B2
(en)
|
2007-08-10 |
2017-07-04 |
E. R. Squibb & Sons, L.L.C. |
HCO32 and HCO27 and related examples
|
CN101820903A
(en)
*
|
2007-08-20 |
2010-09-01 |
美国弗劳恩霍夫股份有限公司 |
Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
|
DK2769729T3
(en)
|
2007-09-04 |
2019-04-23 |
Compugen Ltd |
POLYPEPTIDES AND POLYNUCLEOTIDES AND APPLICATIONS THEREOF AS A PHARMACEUTICAL OBJECTIVE FOR THE PRODUCTION OF MEDICINAL PRODUCTS AND BIOTECHNOLOGICAL PRODUCTS
|
GB0717337D0
(en)
|
2007-09-06 |
2007-10-17 |
Ucb Pharma Sa |
Method of treatment
|
EP2205074A4
(en)
*
|
2007-10-04 |
2013-07-31 |
Harvard College |
Moenomycin analogs, methods of synthesis, and uses thereof
|
TWI489993B
(en)
|
2007-10-12 |
2015-07-01 |
Novartis Ag |
Compositions and methods of use for antibodies against sclerostin
|
ES2627233T3
(en)
|
2007-10-12 |
2017-07-27 |
Massachusetts Institute Of Technology |
Vaccine Nanotechnology
|
US20120040367A1
(en)
*
|
2007-10-15 |
2012-02-16 |
The University Of Queensland |
Construct system and uses therefor
|
EP2567709B1
(en)
|
2007-11-02 |
2017-12-27 |
Novartis AG |
Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6)
|
SG10201605208QA
(en)
|
2007-11-07 |
2016-08-30 |
Celldex Therapeutics Inc |
Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
|
US20090137949A1
(en)
*
|
2007-11-26 |
2009-05-28 |
Bioject Inc. |
Needle-free injection device with nozzle auto-disable
|
US8617099B2
(en)
*
|
2007-11-26 |
2013-12-31 |
Bioject Inc. |
Injection device plunger auto-disable
|
JP5737944B2
(en)
|
2007-12-17 |
2015-06-17 |
ファイザー・リミテッドPfizer Limited |
Treatment of interstitial cystitis
|
WO2009086250A1
(en)
|
2007-12-21 |
2009-07-09 |
Aesthetic Sciences Corporation |
Self-contained pressurized injection device
|
EP2240232A4
(en)
|
2007-12-28 |
2011-03-16 |
Aktivpak Inc |
Dispenser and therapeutic package suitable for administering a therapeutic substance to a subject
|
DE102008011873A1
(en)
|
2007-12-30 |
2009-07-09 |
Idelevich, Evgeny |
Application device for automatically dispensing medicine during blood pressure lowering, has medicine cylinders filled with antidote, where liquid medicine in muscle tissue is injected with help of electro-hydraulical injector
|
EP2237787A4
(en)
*
|
2008-01-03 |
2012-03-21 |
Massachusetts Inst Technology |
Decoy influenza therapies
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
WO2009093189A2
(en)
|
2008-01-22 |
2009-07-30 |
Fundacao De Amparo A Pesquisa Do Estado De Sao Paulo - Fapesp |
Peptides, compositions, and uses thereof
|
BRPI0906387A2
(en)
|
2008-02-05 |
2015-07-07 |
Bristol Myers Squibb Co |
Alpha 5 - beta 1 antibodies and their uses
|
AU2009212273B2
(en)
|
2008-02-08 |
2014-07-31 |
Astrazeneca Ab |
Anti-IFNAR1 antibodies with reduced Fc ligand affinity
|
CA2721060A1
(en)
*
|
2008-04-09 |
2009-10-15 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of fatty acid amide hydrolase
|
MX2010011412A
(en)
|
2008-04-16 |
2010-11-12 |
Glaxosmithkline Biolog Sa |
Vaccine.
|
CA2722743A1
(en)
*
|
2008-04-28 |
2009-11-05 |
Zogenix, Inc. |
Novel formulations for treatment of migraine
|
AU2009243187C1
(en)
*
|
2008-04-28 |
2015-12-24 |
President And Fellows Of Harvard College |
Supercharged proteins for cell penetration
|
PT2439212T
(en)
|
2008-05-02 |
2017-03-29 |
Novartis Ag |
Improved fibronectin-based binding molecules and uses thereof
|
USD994111S1
(en)
|
2008-05-12 |
2023-08-01 |
Kaleo, Inc. |
Medicament delivery device cover
|
US8021344B2
(en)
|
2008-07-28 |
2011-09-20 |
Intelliject, Inc. |
Medicament delivery device configured to produce an audible output
|
RU2010154050A
(en)
*
|
2008-05-30 |
2012-07-10 |
Аллерган, Инк. (Us) |
DEVICE FOR INJECTION OF FILLERS INTENDED FOR INCREASING THE VOLUME OF SOFT TISSUES, BIOACTIVE AGENTS AND OTHER BIOSOCOMPATIBLE MATERIALS IN THE FORM OF LIQUID OR GEL
|
KR20110022000A
(en)
*
|
2008-05-30 |
2011-03-04 |
다나-파버 캔서 인스티튜트 인크. |
Methods of treating a meiotic kinesin-associated disease
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
EP2310412B1
(en)
|
2008-06-20 |
2018-02-21 |
Novartis AG |
Immunoglobulins with reduced aggregation
|
WO2009158687A1
(en)
|
2008-06-26 |
2009-12-30 |
Anterios, Inc. |
Dermal delivery
|
DK2318832T3
(en)
|
2008-07-15 |
2014-01-20 |
Academia Sinica |
Glycan arrays on PTFE-like aluminum coated slides and related methods
|
CA2734991A1
(en)
*
|
2008-07-23 |
2010-01-28 |
Massachusetts Institute Of Technology |
Activation of histone deacetylase 1 (hdac1) protects against dna damage and increases neuronal survival
|
US20110144306A1
(en)
*
|
2008-07-23 |
2011-06-16 |
President And Fellows Of Harvard College |
Ligation of stapled polypeptides
|
CN102177438A
(en)
|
2008-07-25 |
2011-09-07 |
理查德·W·瓦格纳 |
Protein screeing methods
|
AR072999A1
(en)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
|
EP2166021A1
(en)
|
2008-09-16 |
2010-03-24 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies for treatment of cancer
|
EP2326370B1
(en)
*
|
2008-09-18 |
2020-08-05 |
Becton, Dickinson and Company |
Medical injector with slidable sleeve activation
|
EP3530672B1
(en)
|
2008-09-26 |
2024-05-01 |
Dana-Farber Cancer Institute, Inc. |
Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof
|
WO2010037046A1
(en)
|
2008-09-28 |
2010-04-01 |
Fraunhofer Usa, Inc. |
Humanized neuraminidase antibody and methods of use thereof
|
US8343498B2
(en)
*
|
2008-10-12 |
2013-01-01 |
Massachusetts Institute Of Technology |
Adjuvant incorporation in immunonanotherapeutics
|
US8591905B2
(en)
|
2008-10-12 |
2013-11-26 |
The Brigham And Women's Hospital, Inc. |
Nicotine immunonanotherapeutics
|
US8343497B2
(en)
*
|
2008-10-12 |
2013-01-01 |
The Brigham And Women's Hospital, Inc. |
Targeting of antigen presenting cells with immunonanotherapeutics
|
US8277812B2
(en)
|
2008-10-12 |
2012-10-02 |
Massachusetts Institute Of Technology |
Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
|
CN102271707B
(en)
|
2008-10-29 |
2015-04-08 |
阿布林克斯公司 |
Formulations of single domain antigen binding molecules
|
WO2010057197A1
(en)
|
2008-11-17 |
2010-05-20 |
The Regents Of The University Of Michigan |
Cancer vaccine compositions and methods of using the same
|
WO2010065649A1
(en)
*
|
2008-12-02 |
2010-06-10 |
Allergan, Inc. |
Injection device
|
EP2193817A1
(en)
*
|
2008-12-02 |
2010-06-09 |
Sanofi-Aventis Deutschland GmbH |
Drive assembly suitable for use in a medication delivery device and medication delivery device
|
EP2865689A1
(en)
|
2008-12-08 |
2015-04-29 |
Compugen Ltd. |
FAM26F polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
|
WO2010067345A1
(en)
*
|
2008-12-08 |
2010-06-17 |
Perf-Action Technologies Ltd. |
Erosion prevention for o-rings in a high pressure injection device
|
WO2010077806A1
(en)
|
2008-12-15 |
2010-07-08 |
Greenlight Biosciences, Inc. |
Methods for control of flux in metabolic pathways
|
EP3805758A1
(en)
|
2008-12-19 |
2021-04-14 |
Medirista Biotechnologies AB |
Oxidized cardiolipin as a novel pro-inflammatory factor
|
CN105132387A
(en)
*
|
2008-12-22 |
2015-12-09 |
绿光生物科学公司 |
Compositions and methods for the production of a compound
|
MX2011009220A
(en)
|
2009-03-05 |
2011-09-28 |
Medarex Inc |
Fully human antibodies specific to cadm1.
|
GB0904540D0
(en)
|
2009-03-17 |
2009-04-29 |
Biotica Tech Ltd |
Novel compounds and methods for their production
|
EP2416660B1
(en)
|
2009-04-07 |
2014-07-02 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of fatty acid amide hydrolase
|
JP2012523425A
(en)
|
2009-04-07 |
2012-10-04 |
インフイニトイ プハルマセウトイカルス インコーポレイテッド |
Inhibitors of fatty acid amide hydrolase
|
NZ595629A
(en)
|
2009-04-09 |
2013-04-26 |
Amicus Therapeutics Inc |
Methods for preventing and/or treating lysosomal storage disorders
|
EP2419137A4
(en)
*
|
2009-04-17 |
2013-01-09 |
Biogen Idec Inc |
Compositions and methods to treat acute myelogenous leukemia
|
EA030182B1
(en)
|
2009-04-20 |
2018-07-31 |
Оксфорд Байотерепьютикс Лтд. |
Antibodies specific to cadherin-17
|
DK2243505T3
(en)
*
|
2009-04-23 |
2018-04-30 |
Bayer Healthcare Llc |
Spraying devices and methods of producing spraying devices
|
EP2424894A1
(en)
|
2009-04-27 |
2012-03-07 |
Novartis AG |
Composition and methods of use for therapeutic antibodies specific for the il-12 receptore betal subunit
|
EP3275900A1
(en)
|
2009-04-27 |
2018-01-31 |
Novartis AG |
Compositions and methods for increasing muscle growth
|
US9221886B2
(en)
|
2009-04-28 |
2015-12-29 |
President And Fellows Of Harvard College |
Supercharged proteins for cell penetration
|
ES2514319T3
(en)
|
2009-05-04 |
2014-10-28 |
Abbvie Research B.V. |
Antibodies against nerve growth factor (NGF) with improved in vivo stability
|
AU2010249046A1
(en)
|
2009-05-13 |
2011-12-01 |
Sea Lane Biotechnologies, Llc |
Neutralizing molecules to influenza viruses
|
US8927551B2
(en)
*
|
2009-05-18 |
2015-01-06 |
Infinity Pharmaceuticals, Inc. |
Isoxazolines as inhibitors of fatty acid amide hydrolase
|
US8765735B2
(en)
*
|
2009-05-18 |
2014-07-01 |
Infinity Pharmaceuticals, Inc. |
Isoxazolines as inhibitors of fatty acid amide hydrolase
|
US9149465B2
(en)
*
|
2009-05-18 |
2015-10-06 |
Infinity Pharmaceuticals, Inc. |
Isoxazolines as inhibitors of fatty acid amide hydrolase
|
US8974423B2
(en)
*
|
2009-06-01 |
2015-03-10 |
Sanofi-Aventis Deutschland Gmbh |
Resettable drug delivery device
|
CA2769999C
(en)
|
2009-06-01 |
2020-02-18 |
Shriners Hospitals For Children |
A cloned transmembrane receptor for 24-hydroxylated vitamin d compounds and uses thereof
|
JP2012528858A
(en)
|
2009-06-01 |
2012-11-15 |
プレジデント アンド フェロウズ オブ ハーバード カレッジ |
O-GlcNAc transferase inhibitor and use thereof
|
KR20180056805A
(en)
|
2009-06-04 |
2018-05-29 |
노파르티스 아게 |
METHODS FOR IDENTIFICATION OF SITES FOR IgG CONJUGATION
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
US9163330B2
(en)
|
2009-07-13 |
2015-10-20 |
President And Fellows Of Harvard College |
Bifunctional stapled polypeptides and uses thereof
|
SG177689A1
(en)
|
2009-07-31 |
2012-02-28 |
Organon Nv |
Fully human antibodies to btla
|
US8394922B2
(en)
|
2009-08-03 |
2013-03-12 |
Medarex, Inc. |
Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
|
GB0913681D0
(en)
|
2009-08-05 |
2009-09-16 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
GB0914589D0
(en)
|
2009-08-20 |
2009-09-30 |
Biotica Tech Ltd |
Novel compounds and methods for their production
|
WO2011029823A1
(en)
|
2009-09-09 |
2011-03-17 |
Novartis Ag |
Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
|
GB0916630D0
(en)
|
2009-09-22 |
2009-11-04 |
Secr Defence |
Antibody
|
CA2774973A1
(en)
|
2009-09-22 |
2011-03-31 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
WO2011041391A1
(en)
|
2009-09-29 |
2011-04-07 |
Fraunhofer Usa, Inc. |
Influenza hemagglutinin antibodies, compositions, and related methods
|
GB0917816D0
(en)
|
2009-10-12 |
2009-11-25 |
Biotica Tech Ltd |
Novel compounds and methods for their production
|
GB0917817D0
(en)
|
2009-10-12 |
2009-11-25 |
Biotica Tech Ltd |
Novel compounds and methods for their production
|
US20120231004A1
(en)
|
2009-10-13 |
2012-09-13 |
Oxford Biotherapeutic Ltd. |
Antibodies
|
CA2777242A1
(en)
|
2009-10-14 |
2011-04-21 |
Merrimack Pharmaceuticals, Inc. |
Bispecific binding agents targeting igf-1r and erbb3 signalling and uses thereof
|
JP6147005B2
(en)
|
2009-10-19 |
2017-06-14 |
アミカス セラピューティックス インコーポレイテッド |
Novel composition for preventing and / or treating lysosomal storage disorders
|
RU2015147509A
(en)
|
2009-10-19 |
2019-01-14 |
Амикус Терапьютикс, Инк. |
NEW COMPOSITIONS FOR PREVENTING AND / OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM
|
WO2011051327A2
(en)
|
2009-10-30 |
2011-05-05 |
Novartis Ag |
Small antibody-like single chain proteins
|
WO2011051466A1
(en)
|
2009-11-02 |
2011-05-05 |
Novartis Ag |
Anti-idiotypic fibronectin-based binding molecules and uses thereof
|
US20120282276A1
(en)
|
2009-11-05 |
2012-11-08 |
The Regents Of The University Of Michigan |
Biomarkers predictive of progression of fibrosis
|
US9428586B2
(en)
|
2009-12-01 |
2016-08-30 |
Compugen Ltd |
Heparanase splice variant
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US20110137260A1
(en)
|
2009-12-07 |
2011-06-09 |
Allergan, Inc. |
Slotted syringe
|
AR079494A1
(en)
|
2009-12-18 |
2012-02-01 |
Novartis Ag |
ORGANIC COMPOSITIONS TO TREAT DISEASES RELATED TO THE HEAT SHOCK FACTOR 1 HSF1
|
MX2012007318A
(en)
|
2009-12-22 |
2012-07-20 |
Novartis Ag |
Tetravalent cd47-antibody constant region fusion protein for use in therapy.
|
US9180127B2
(en)
|
2009-12-29 |
2015-11-10 |
Dana-Farber Cancer Institute, Inc. |
Type II Raf kinase inhibitors
|
AU2011210840B2
(en)
|
2010-01-27 |
2014-12-11 |
Massachusetts Institute Of Technology |
Engineered polypeptide agents for targeted broad spectrum influenza neutralization
|
WO2011092233A1
(en)
|
2010-01-29 |
2011-08-04 |
Novartis Ag |
Yeast mating to produce high-affinity combinations of fibronectin-based binders
|
MX361011B
(en)
*
|
2010-02-03 |
2018-11-26 |
Infinity Pharmaceuticals Inc |
Fatty acid amide hydrolase inhibitors.
|
EA201201113A1
(en)
|
2010-02-10 |
2013-03-29 |
Новартис Аг |
METHODS AND CONNECTIONS FOR GROWTH OF MUSCLE
|
WO2011112635A1
(en)
|
2010-03-08 |
2011-09-15 |
Sloan-Kettering Institute For Cancer Research |
Cdc7 kinase inhibitors and uses thereof
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
GB201003920D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Method of treatment
|
NZ602054A
(en)
|
2010-03-17 |
2014-10-31 |
Abbott Res Bv |
Anti-nerve growth factor (ngf) antibody compositions
|
US9102697B2
(en)
|
2010-03-22 |
2015-08-11 |
President And Fellows Of Harvard College |
Trioxacarcins and uses thereof
|
EP2371864A1
(en)
|
2010-03-23 |
2011-10-05 |
Ganymed Pharmaceuticals AG |
Monoclonal antibodies for treatment of cancer
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
CN103119054B
(en)
|
2010-03-26 |
2017-01-18 |
达特茅斯大学理事会 |
VISTA regulatory T cell mediator protein, VISTA binding agents and use thereof
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
JP6002659B2
(en)
|
2010-04-13 |
2016-10-05 |
セルデックス・セラピューティクス・インコーポレイテッド |
Antibodies that bind to human CD27 and uses thereof
|
DK3466977T3
(en)
|
2010-04-16 |
2022-04-11 |
Biogen Ma Inc |
Anti-vla-4-antistoffer
|
US9795658B2
(en)
|
2010-04-20 |
2017-10-24 |
Admedus Vaccines Pty Ltd |
Expression system for modulating an immune response
|
AR081082A1
(en)
|
2010-04-23 |
2012-06-06 |
Novartis Ag |
ORGANIC COMPOSITIONS TO TREAT DISEASES RELATED TO BETA-ENAC
|
WO2011140151A1
(en)
|
2010-05-04 |
2011-11-10 |
Dyax Corp. |
Antibodies against epidermal growth factor receptor (egfr)
|
WO2011140254A1
(en)
|
2010-05-04 |
2011-11-10 |
Adimab, Llc |
Antibodies against epidermal growth factor receptor (egfr) and uses thereof
|
WO2011140296A1
(en)
|
2010-05-05 |
2011-11-10 |
Infinity Pharmaceuticals |
Triazoles as inhibitors of fatty acid synthase
|
EP2566853B1
(en)
|
2010-05-05 |
2017-01-25 |
Infinity Pharmaceuticals, Inc. |
Tetrazolones as inhibitors of fatty acid synthase
|
DK2566953T3
(en)
|
2010-05-07 |
2019-04-15 |
Greenlight Biosciences Inc |
METHODS OF MANAGING THE POWER BY METABOLIC ROADS USING ENZYMOUS LOCATION
|
CN106977429B
(en)
|
2010-05-11 |
2021-08-24 |
蓝瑟斯医学影像公司 |
Compositions, methods and systems for synthesis and use of contrast agents
|
WO2011146713A1
(en)
|
2010-05-19 |
2011-11-24 |
Allergan, Inc. |
Modular injection device
|
ES2664872T3
(en)
|
2010-06-18 |
2018-04-23 |
Taiho Pharmaceutical Co., Ltd |
PRPK-TPRKB modulators and their uses
|
EP3202415B1
(en)
|
2010-06-30 |
2021-12-08 |
Compugen Ltd. |
Fusion protein comprising a c1orf32 polypeptide and one or more domains of an immunoglobulin heavy chain constant region for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders.
|
US9072713B2
(en)
|
2010-07-01 |
2015-07-07 |
The Texas A&M University System |
Perlecan domain V protects, repairs and restores ischemic brain stroke injury and motor function
|
CN108314733A
(en)
|
2010-07-16 |
2018-07-24 |
埃博灵克斯股份有限公司 |
The single domain antigen binding molecules of modification and its application
|
WO2012019168A2
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
PT2603600T
(en)
|
2010-08-13 |
2019-02-27 |
Aileron Therapeutics Inc |
Peptidomimetic macrocycles
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
WO2012030980A1
(en)
|
2010-08-31 |
2012-03-08 |
Greenlight Biosciences, Inc. |
Methods for control of flux in metabolic pathways through protease manipulation
|
US8734384B2
(en)
*
|
2010-09-15 |
2014-05-27 |
Zogenix, Inc. |
Needle-free injectors and design parameters thereof that optimize injection performance
|
US8999335B2
(en)
|
2010-09-17 |
2015-04-07 |
Compugen Ltd. |
Compositions and methods for treatment of drug resistant multiple myeloma
|
JP2013541528A
(en)
|
2010-09-21 |
2013-11-14 |
マサチューセッツ インスティテュート オブ テクノロジー |
Human adaptive HA polypeptides, vaccines, and influenza treatment
|
US8957026B2
(en)
|
2010-09-22 |
2015-02-17 |
President And Fellows Of Harvard College |
Beta-catenin targeting peptides and uses thereof
|
US9388230B2
(en)
|
2010-09-28 |
2016-07-12 |
Kahr Medical(2005) Ltd |
Compositions and methods for treatment of hematological malignancies
|
AU2011308906B2
(en)
|
2010-10-01 |
2016-06-16 |
Biogen Ma Inc. |
Interferon-beta for use as monotherapy or in combination with other cancer therapies
|
US20120237975A1
(en)
|
2010-10-01 |
2012-09-20 |
Jason Schrum |
Engineered nucleic acids and methods of use thereof
|
WO2012045085A1
(en)
|
2010-10-01 |
2012-04-05 |
Oxford Biotherapeutics Ltd. |
Anti-rori antibodies
|
WO2012047941A2
(en)
|
2010-10-04 |
2012-04-12 |
Massachusetts Institute Of Technology |
Hemagglutinin polypeptides, and reagents and methods relating thereto
|
JP2013543384A
(en)
|
2010-10-05 |
2013-12-05 |
ノバルティス アーゲー |
Anti-IL12Rbeta1 antibody and its use in the treatment of autoimmune and inflammatory diseases
|
CN103269729A
(en)
|
2010-11-03 |
2013-08-28 |
尤尔科医疗有限公司 |
Portable vacuum device
|
CN103298474B
(en)
|
2010-11-10 |
2016-06-29 |
无限药品股份有限公司 |
Heterocyclic compound and application thereof
|
SG190321A1
(en)
|
2010-11-24 |
2013-06-28 |
Novartis Int Pharm Ltd |
Fusion enzymes having n-acetylglucosaminyltransferase activity
|
GB201100282D0
(en)
|
2011-01-07 |
2011-02-23 |
Ucb Pharma Sa |
Biological methods
|
US10208349B2
(en)
|
2011-01-07 |
2019-02-19 |
Ucb Biopharma Sprl |
Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
|
NZ612909A
(en)
|
2011-01-10 |
2015-09-25 |
Infinity Pharmaceuticals Inc |
Processes for preparing isoquinolinones and solid forms of isoquinolinones
|
EP2982373B1
(en)
|
2011-01-19 |
2018-06-13 |
Topokine Therapeutics, Inc. |
Methods and compostions for reducing body fat
|
KR20230007537A
(en)
|
2011-01-24 |
2023-01-12 |
안테리오스, 인코퍼레이티드 |
Nanoparticle compositions, formulations thereof, and uses therefor
|
WO2012103035A1
(en)
|
2011-01-24 |
2012-08-02 |
Anterios, Inc. |
Nanoparticle compositions
|
JP2014503586A
(en)
|
2011-01-24 |
2014-02-13 |
アンテリオス, インコーポレイテッド |
Oil composition
|
US8939943B2
(en)
|
2011-01-26 |
2015-01-27 |
Kaleo, Inc. |
Medicament delivery device for administration of opioid antagonists including formulations for naloxone
|
US8627816B2
(en)
|
2011-02-28 |
2014-01-14 |
Intelliject, Inc. |
Medicament delivery device for administration of opioid antagonists including formulations for naloxone
|
US9084849B2
(en)
|
2011-01-26 |
2015-07-21 |
Kaleo, Inc. |
Medicament delivery devices for administration of a medicament within a prefilled syringe
|
US8703818B2
(en)
|
2011-03-03 |
2014-04-22 |
Tersus Pharmaceuticals, LLC |
Compositions and methods comprising C16:1n7-palmitoleate
|
WO2012119989A2
(en)
|
2011-03-04 |
2012-09-13 |
Oryzon Genomics, S.A. |
Methods and antibodies for the diagnosis and treatment of cancer
|
GB201103836D0
(en)
|
2011-03-07 |
2011-04-20 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
US9193767B2
(en)
|
2011-03-30 |
2015-11-24 |
Brown University |
Enopeptins, uses thereof, and methods of synthesis thereto
|
US20130281932A1
(en)
*
|
2011-03-30 |
2013-10-24 |
Ziv Harish |
Palm-based injector actuation and safety surfaces
|
AU2012236099A1
(en)
|
2011-03-31 |
2013-10-03 |
Moderna Therapeutics, Inc. |
Delivery and formulation of engineered nucleic acids
|
US9409987B2
(en)
|
2011-04-15 |
2016-08-09 |
Compugen Ltd |
Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
|
RU2013151159A
(en)
*
|
2011-04-19 |
2015-05-27 |
ИНВИЗИДЕРМ, ЭлЭлСи |
METHOD FOR CREATING SUBSTANCES THAT OVERSATURATED WITH GAS, DEVICE FOR TRANSDERMAL DELIVERY AND ITS USE
|
CN103533953A
(en)
|
2011-05-17 |
2014-01-22 |
葛兰素史密丝克莱恩生物有限公司 |
Vaccine against streptococcus pneumoniae
|
US8691231B2
(en)
|
2011-06-03 |
2014-04-08 |
Merrimack Pharmaceuticals, Inc. |
Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
|
WO2012172521A1
(en)
|
2011-06-16 |
2012-12-20 |
Novartis Ag |
Soluble proteins for use as therapeutics
|
WO2012177595A1
(en)
|
2011-06-21 |
2012-12-27 |
Oncofactor Corporation |
Compositions and methods for the therapy and diagnosis of cancer
|
AU2012272815B2
(en)
|
2011-06-22 |
2017-09-07 |
The General Hospital Corporation |
Treatment of proteinopathies
|
JP6247209B2
(en)
|
2011-06-28 |
2017-12-13 |
オックスフォード ビオトヘラペウトイクス エルティーディー. |
Antibody to ADP ribosyl cyclase 2
|
AU2012277376B2
(en)
|
2011-06-30 |
2016-11-24 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
PL2726099T3
(en)
|
2011-07-01 |
2018-12-31 |
Novartis Ag |
Method for treating metabolic disorders
|
US8969363B2
(en)
|
2011-07-19 |
2015-03-03 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
MX2014000648A
(en)
|
2011-07-19 |
2014-09-25 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof.
|
US9115053B2
(en)
|
2011-07-22 |
2015-08-25 |
Massachusetts Institute Of Technology |
Activators of class I histone deacetlyases (HDACS) and uses thereof
|
EP2736928B1
(en)
|
2011-07-28 |
2019-01-09 |
i2 Pharmaceuticals, Inc. |
Sur-binding proteins against erbb3
|
TW201311663A
(en)
|
2011-08-29 |
2013-03-16 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
MX2014002536A
(en)
|
2011-09-02 |
2014-09-01 |
Novartis Ag |
Organic compositions to treat hsf1-related diseases.
|
WO2013036787A2
(en)
|
2011-09-09 |
2013-03-14 |
Greenlight Biosciences, Inc. |
Cell-free preparation of carbapenems
|
SG2014013767A
(en)
|
2011-09-09 |
2014-05-29 |
Lantheus Medical Imaging Inc |
Compositions, methods, and systems for the synthesis and use of imaging agents
|
EP3384938A1
(en)
|
2011-09-12 |
2018-10-10 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
WO2013043569A1
(en)
|
2011-09-20 |
2013-03-28 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
US8987422B2
(en)
|
2011-09-22 |
2015-03-24 |
Amgen Inc. |
CD27L antigen binding proteins
|
WO2013049332A1
(en)
|
2011-09-29 |
2013-04-04 |
Infinity Pharmaceuticals, Inc. |
Inhibitors of monoacylglycerol lipase and methods of their use
|
EP3682905B1
(en)
|
2011-10-03 |
2021-12-01 |
ModernaTX, Inc. |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
RU2474437C1
(en)
*
|
2011-10-13 |
2013-02-10 |
Борис Владимирович Смоляров |
Needle-free injection technique
|
US20130096170A1
(en)
|
2011-10-14 |
2013-04-18 |
Hospira, Inc. |
Methods of treating pediatric patients using dexmedetomidine
|
CA2852468A1
(en)
|
2011-10-18 |
2013-04-25 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocyles
|
CN104039320B
(en)
|
2011-11-09 |
2019-10-15 |
百时美施贵宝公司 |
The treatment of the anti-CXCR4 antibody of hematologic malignancies
|
US9382239B2
(en)
|
2011-11-17 |
2016-07-05 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-Jun-N-terminal kinase (JNK)
|
US8603028B2
(en)
|
2011-11-18 |
2013-12-10 |
Allergan, Inc. |
Injection device having an angled tip portion
|
GB201120000D0
(en)
|
2011-11-20 |
2012-01-04 |
Glaxosmithkline Biolog Sa |
Vaccine
|
GB201119999D0
(en)
|
2011-11-20 |
2012-01-04 |
Glaxosmithkline Biolog Sa |
Vaccine
|
RS63244B1
(en)
|
2011-12-16 |
2022-06-30 |
Modernatx Inc |
Modified mrna compositions
|
CN104114170B
(en)
|
2011-12-16 |
2021-07-06 |
佛罗里达大学研究基金会 |
Use of 4' -deferthionin analogues
|
US8426471B1
(en)
|
2011-12-19 |
2013-04-23 |
Topokine Therapeutics, Inc. |
Methods and compositions for reducing body fat and adipocytes
|
WO2013096828A1
(en)
|
2011-12-22 |
2013-06-27 |
Sea Lane Biotechnologies, Llc |
Surrogate binding proteins
|
GB201122305D0
(en)
|
2011-12-23 |
2012-02-01 |
Biotica Tech Ltd |
Novel compound
|
US8242158B1
(en)
|
2012-01-04 |
2012-08-14 |
Hospira, Inc. |
Dexmedetomidine premix formulation
|
MX355226B
(en)
|
2012-01-05 |
2018-03-23 |
Glykos Finland Oy |
Protease deficient filamentous fungal cells and methods of use thereof.
|
CN104302768A
(en)
|
2012-01-09 |
2015-01-21 |
诺华股份有限公司 |
Rnai agents to treat beta-catenin related diseases
|
US10130800B2
(en)
|
2012-01-27 |
2018-11-20 |
Invisiderm, Llc |
Method of producing substances with supersaturated gas, transdermal delivery device thereof, and uses thereof
|
IN2014KN00848A
(en)
|
2012-02-01 |
2015-10-02 |
Compugen Ltd |
|
WO2013122823A1
(en)
|
2012-02-13 |
2013-08-22 |
Bristol-Myers Squibb Company |
Enediyne compounds, conjugates thereof, and uses and methods therefor
|
RU2017145921A
(en)
|
2012-02-15 |
2019-02-21 |
Эйлерон Терапьютикс, Инк. |
PEPTIDOMIMETIC MACROCYCLES
|
CA2864120A1
(en)
|
2012-02-15 |
2013-08-22 |
Aileron Therapeutics, Inc. |
Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
|
US20150079100A1
(en)
|
2012-03-23 |
2015-03-19 |
Bristol-Myers Squibb Company |
Methods of treatments using ctla-4 antibodies
|
CA2868459A1
(en)
|
2012-03-27 |
2013-10-03 |
Amicus Therapeutics, Inc. |
Polymorphs of (3r,4r,5s)-5-(difluoromethyl)piperidine-3,4-diol fumarate and uses thereof
|
EP2830659A1
(en)
|
2012-03-27 |
2015-02-04 |
Novartis AG |
Treatment of fibrosis
|
US9273084B2
(en)
|
2012-04-06 |
2016-03-01 |
President And Fellows Of Harvard College |
Moenomycin analogs, methods of synthesis, and uses thereof
|
EP2850091A1
(en)
|
2012-04-06 |
2015-03-25 |
President and Fellows of Harvard College |
Methods and compounds for identifying glycosyltransferase inhibitors
|
EP2850090B1
(en)
|
2012-04-06 |
2018-10-03 |
President and Fellows of Harvard College |
Chemoenzymatic methods for synthesizing moenomycin analogs
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
US9597385B2
(en)
|
2012-04-23 |
2017-03-21 |
Allertein Therapeutics, Llc |
Nanoparticles for treatment of allergy
|
WO2013167153A1
(en)
|
2012-05-09 |
2013-11-14 |
Ganymed Pharmaceuticals Ag |
Antibodies useful in cancer diagnosis
|
US20130304017A1
(en)
*
|
2012-05-09 |
2013-11-14 |
Bioject, Inc. |
Peformance of needle-free injection according to known relationships
|
EP2846833A4
(en)
|
2012-05-10 |
2016-01-06 |
Massachusetts Inst Technology |
Agents for influenza neutralization
|
US9969794B2
(en)
|
2012-05-10 |
2018-05-15 |
Visterra, Inc. |
HA binding agents
|
WO2013173582A1
(en)
|
2012-05-17 |
2013-11-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Hepatitis c virus neutralizing antibody
|
UY34813A
(en)
|
2012-05-18 |
2013-11-29 |
Amgen Inc |
ANTIGEN UNION PROTEINS DIRECTED AGAINST ST2 RECEIVER
|
US9522235B2
(en)
|
2012-05-22 |
2016-12-20 |
Kaleo, Inc. |
Devices and methods for delivering medicaments from a multi-chamber container
|
EP2852610B1
(en)
|
2012-05-23 |
2018-07-11 |
Glykos Finland Oy |
Production of fucosylated glycoproteins
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
CA2875683A1
(en)
|
2012-06-05 |
2013-12-12 |
The Australian National University |
Vaccination with interleukin-4 antagonists
|
GB201210082D0
(en)
*
|
2012-06-07 |
2012-07-25 |
Consort Medical Plc |
Improved syringe
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
AR091649A1
(en)
|
2012-07-02 |
2015-02-18 |
Bristol Myers Squibb Co |
OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
|
CA2879939A1
(en)
|
2012-08-06 |
2014-02-13 |
Glaxosmithkline Biologicals S.A. |
Novel method
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
US10309430B2
(en)
*
|
2012-08-10 |
2019-06-04 |
Confluent Surgical, Inc. |
Pneumatic actuation assembly
|
AU2013203000B9
(en)
|
2012-08-10 |
2017-02-02 |
Lantheus Medical Imaging, Inc. |
Compositions, methods, and systems for the synthesis and use of imaging agents
|
WO2014028463A1
(en)
|
2012-08-14 |
2014-02-20 |
Allergan, Inc. |
Syringe for mixing and dispensing adipose tissue
|
AU2013306098A1
(en)
|
2012-08-18 |
2015-02-12 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
AU2013312211B2
(en)
|
2012-09-07 |
2018-03-29 |
King's College London |
VISTA modulators for diagnosis and treatment of cancer
|
WO2014052647A2
(en)
|
2012-09-26 |
2014-04-03 |
President And Fellows Of Harvard College |
Proline-locked stapled peptides and uses thereof
|
US20150225471A1
(en)
|
2012-10-01 |
2015-08-13 |
President And Fellows Of Harvard College |
Stabilized polypeptide insulin receptor modulators
|
PT2909204T
(en)
|
2012-10-12 |
2019-03-21 |
Dana Farber Cancer Inst Inc |
Gsk3 inhibitors and methods of use thereof
|
WO2014063068A1
(en)
|
2012-10-18 |
2014-04-24 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (cdk7)
|
USRE48175E1
(en)
|
2012-10-19 |
2020-08-25 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged small molecules as inducers of protein degradation
|
US10000483B2
(en)
|
2012-10-19 |
2018-06-19 |
Dana-Farber Cancer Institute, Inc. |
Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
|
US9675754B2
(en)
|
2012-10-24 |
2017-06-13 |
Nuance Designs, LLC |
Autoinjector
|
WO2014065822A1
(en)
|
2012-10-26 |
2014-05-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Hepatitis c virus neutralizing epitopes, antibodies, and methods
|
BR112015009470A2
(en)
|
2012-11-01 |
2019-12-17 |
Aileron Therapeutics Inc |
disubstituted amino acids and their methods of preparation and use
|
SI2914296T2
(en)
|
2012-11-01 |
2022-01-31 |
Infinity Pharmaceuticals, Inc. |
Treatment of cancers using pi3 kinase isoform modulators
|
WO2014071247A1
(en)
|
2012-11-02 |
2014-05-08 |
Dana-Farber Cancer Institute, Inc. |
Pyrrol-1 -yl benzoic acid derivates useful as myc inhibitors
|
CN104936632B
(en)
*
|
2012-11-13 |
2017-08-04 |
康斯特鲁科特医疗有限公司 |
Portable aspirator
|
SG11201600237YA
(en)
|
2012-11-21 |
2016-02-26 |
Topokine Therapeutics Inc |
Methods and compositions for locally increasing body fat
|
WO2014082065A1
(en)
|
2012-11-26 |
2014-05-30 |
President And Fellows Of Harvard College |
Trioxacarcins, trioxacarcin-antibody conjugates, and uses thereof
|
ES2921623T3
(en)
|
2012-11-26 |
2022-08-30 |
Modernatx Inc |
terminally modified RNA
|
EP3686218A1
(en)
|
2012-12-10 |
2020-07-29 |
Biogen MA Inc. |
Anti-blood dendritic cell antigen 2 antibodies and uses thereof
|
SI2935320T1
(en)
|
2012-12-18 |
2019-12-31 |
Novartis Ag |
Stabilized insulin-like growth factor polypeptides
|
CA2899363A1
(en)
|
2012-12-21 |
2014-06-26 |
Epizyme, Inc. |
Prmt5 inhibitors and uses thereof
|
WO2014100730A1
(en)
|
2012-12-21 |
2014-06-26 |
Epizyme, Inc. |
Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
|
WO2014100695A1
(en)
|
2012-12-21 |
2014-06-26 |
Epizyme, Inc. |
Prmt5 inhibitors and uses thereof
|
PL2935222T3
(en)
|
2012-12-21 |
2019-02-28 |
Epizyme Inc |
Prmt5 inhibitors and uses thereof
|
CA2896708A1
(en)
|
2012-12-27 |
2014-07-03 |
Kaleo, Inc. |
Devices, systems and methods for locating and interacting with medicament delivery systems
|
WO2014113089A2
(en)
|
2013-01-17 |
2014-07-24 |
Moderna Therapeutics, Inc. |
Signal-sensor polynucleotides for the alteration of cellular phenotypes
|
WO2014114801A1
(en)
|
2013-01-25 |
2014-07-31 |
Amgen Inc. |
Antibodies targeting cdh19 for melanoma
|
JO3519B1
(en)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
Antibody constructs for CDH19 and CD3
|
WO2014124319A2
(en)
|
2013-02-07 |
2014-08-14 |
Massachusetts Institute Of Technology |
Human adaptation of h5 influenza
|
AU2014214844B2
(en)
|
2013-02-07 |
2017-12-14 |
Children's Medical Center Corporation |
Protein antigens that provide protection against pneumococcal colonization and/or disease
|
MX371052B
(en)
|
2013-02-08 |
2020-01-14 |
Novartis Ag |
Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders.
|
DK2956173T3
(en)
|
2013-02-14 |
2017-07-17 |
Bristol Myers Squibb Co |
TUBULYSIS RELATIONSHIPS, METHODS OF PRODUCING AND USING THEREOF
|
WO2014133855A1
(en)
|
2013-02-28 |
2014-09-04 |
Caprion Proteomics Inc. |
Tuberculosis biomarkers and uses thereof
|
KR20150131244A
(en)
|
2013-03-13 |
2015-11-24 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
Stapled and stitched polypeptides and uses thereof
|
WO2014159813A1
(en)
|
2013-03-13 |
2014-10-02 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
BR112015017307A2
(en)
|
2013-03-14 |
2017-11-21 |
Abbvie Inc |
compositions of low acid species and methods for their production and use
|
AU2014240431A1
(en)
|
2013-03-14 |
2015-08-27 |
Abbvie Inc. |
Low acidic species compositions and methods for producing the same using displacement chromatography
|
US10035859B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
WO2014143739A2
(en)
|
2013-03-15 |
2014-09-18 |
Biogen Idec Ma Inc. |
Anti-alpha v beta 6 antibodies and uses thereof
|
US9505849B2
(en)
|
2013-03-15 |
2016-11-29 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza M2 and CD3
|
WO2014151680A1
(en)
|
2013-03-15 |
2014-09-25 |
Biogen Idec Ma Inc. |
Treatment and prevention of acute kidney injury using anti-alpha v beta 5 antibodies
|
US9308236B2
(en)
|
2013-03-15 |
2016-04-12 |
Bristol-Myers Squibb Company |
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
|
HUE045859T2
(en)
|
2013-03-15 |
2020-01-28 |
Amgen Res Munich Gmbh |
Single chain binding molecules comprising n-terminal abp
|
WO2014151386A1
(en)
|
2013-03-15 |
2014-09-25 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
EP2981285B1
(en)
|
2013-04-03 |
2020-06-03 |
N-Fold Llc |
Novel nanoparticle compositions
|
JP6437523B2
(en)
|
2013-04-04 |
2018-12-12 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
Macrolides and methods for their preparation and use
|
US9381253B2
(en)
|
2013-04-09 |
2016-07-05 |
Massachusetts Institute Of Technology |
Drug delivery polymer and uses thereof
|
WO2014179464A1
(en)
|
2013-04-30 |
2014-11-06 |
Massachusetts Institute Of Technology |
Human adaptation of h3 influenza
|
US9315472B2
(en)
|
2013-05-01 |
2016-04-19 |
Massachusetts Institute Of Technology |
1,3,5-triazinane-2,4,6-trione derivatives and uses thereof
|
NO2753788T3
(en)
|
2013-05-10 |
2018-06-16 |
|
|
US9820993B2
(en)
|
2013-05-15 |
2017-11-21 |
Topokine Therapeutics, Inc. |
Methods and compositions for topical delivery of prostaglandins to subcutaneous fat
|
US20140350518A1
(en)
|
2013-05-23 |
2014-11-27 |
Allergan, Inc. |
Syringe extrusion accessory
|
US20140350516A1
(en)
|
2013-05-23 |
2014-11-27 |
Allergan, Inc. |
Mechanical syringe accessory
|
MX351127B
(en)
|
2013-05-30 |
2017-10-03 |
Kiniksa Pharmaceuticals Ltd |
Oncostatin m receptor antigen binding proteins.
|
SG11201509842SA
(en)
|
2013-05-30 |
2015-12-30 |
Infinity Pharmaceuticals Inc |
Treatment of cancers using pi3 kinase isoform modulators
|
WO2014197723A2
(en)
|
2013-06-05 |
2014-12-11 |
Massachusetts Institute Of Technology |
Human adaptation of h7 ha
|
US9212145B2
(en)
|
2013-06-11 |
2015-12-15 |
Kala Pharmaceuticals, Inc. |
Urea derivatives and uses thereof
|
CN105492460A
(en)
|
2013-06-14 |
2016-04-13 |
哈佛大学的校长及成员们 |
Stabilized polypeptide insulin receptor modulators
|
EP3013365B1
(en)
|
2013-06-26 |
2019-06-05 |
Academia Sinica |
Rm2 antigens and use thereof
|
EP4001275A1
(en)
|
2013-06-26 |
2022-05-25 |
Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH |
(s)-enantiomer of mepazine as paracaspase (malt1) inhibitor for the treatment of cancer
|
WO2014210564A1
(en)
|
2013-06-27 |
2014-12-31 |
Academia Sinica |
Glycan conjugates and use thereof
|
AU2014292888B2
(en)
|
2013-07-25 |
2018-03-22 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of transcription factors and uses thereof
|
BR112016002494A2
(en)
|
2013-08-05 |
2017-09-05 |
Greenlight Biosciences Inc |
PROTEINS CONSTRUCTED WITH A PROTEASE CLEAVAGE SITE, NUCLEIC ACID, VECTOR, CELL AND PROCESS ENGINEERING A RECOMBINANT PROTEIN AND A LARGE NUMBER OF NUCLEIC ACID VARIANTS THAT ENCODE RECOMBINANT PROTEINS
|
EP3492097A1
(en)
|
2013-08-05 |
2019-06-05 |
GlaxoSmithKline Biologicals S.A. |
Combination immunogenic compositions
|
TWI532511B
(en)
*
|
2013-08-16 |
2016-05-11 |
京華堂實業股份有限公司 |
A needleless drug-injecting system and a drug-injecting method thereof
|
CN105682666B
(en)
|
2013-09-06 |
2021-06-01 |
中央研究院 |
Activation of human iNKT cells using glycolipids
|
AR097648A1
(en)
|
2013-09-13 |
2016-04-06 |
Amgen Inc |
COMBINATION OF EPIGENETIC FACTORS AND BIESPECTIVE COMPOUNDS THAT HAVE LIKE DIANA CD33 AND CD3 IN THE TREATMENT OF MYELOID LEUKEMIA
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
CA2926173A1
(en)
|
2013-10-02 |
2015-04-09 |
Novartis Ag |
Insulin-like growth factor mimetics for use in therapy
|
NZ718430A
(en)
|
2013-10-04 |
2021-12-24 |
Infinity Pharmaceuticals Inc |
Heterocyclic compounds and uses thereof
|
US9751888B2
(en)
|
2013-10-04 |
2017-09-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
US20160243224A1
(en)
|
2013-10-04 |
2016-08-25 |
Biogen Ma Inc. |
Tweak antagonists for treating lupus nephritis and muscle atrophy
|
US10081682B2
(en)
|
2013-10-11 |
2018-09-25 |
Oxford Bio Therapeutics Ltd. |
Conjugated antibodies against LY75 for the treatment of cancer
|
WO2015057894A1
(en)
|
2013-10-15 |
2015-04-23 |
Massachusetts Institute Of Technology |
Methods for treating polycystic kidney disease and polycystic liver disease
|
US9902986B2
(en)
|
2013-10-16 |
2018-02-27 |
Massachusetts Institute Of Technology |
Enterobactin conjugates and uses thereof
|
US10047070B2
(en)
|
2013-10-18 |
2018-08-14 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
|
WO2015057939A1
(en)
|
2013-10-18 |
2015-04-23 |
Biogen Idec Ma Inc. |
Anti-s1p4 antibodies and uses thereof
|
EP3057955B1
(en)
|
2013-10-18 |
2018-04-11 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
WO2015061204A1
(en)
|
2013-10-21 |
2015-04-30 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2015066482A1
(en)
|
2013-11-01 |
2015-05-07 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
UY35874A
(en)
|
2013-12-12 |
2015-07-31 |
Novartis Ag |
A PROCESS FOR THE PREPARATION OF A COMPOSITION OF PEGILATED PROTEINS
|
EP3083685A2
(en)
|
2013-12-20 |
2016-10-26 |
Intervet International B.V. |
Canine antibodies with modified ch2-ch3 sequences
|
TWI728373B
(en)
|
2013-12-23 |
2021-05-21 |
美商建南德克公司 |
Antibodies and methods of use
|
KR20160101162A
(en)
|
2013-12-24 |
2016-08-24 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
Cortistatin analogues and syntheses and uses thereof
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
EP3087098B1
(en)
|
2013-12-24 |
2020-04-08 |
Janssen Pharmaceutica NV |
Anti-vista antibodies and fragments
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
EP3094352B1
(en)
|
2014-01-16 |
2020-09-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
JP2017504651A
(en)
|
2014-01-31 |
2017-02-09 |
ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド |
Use of diazepan derivatives
|
JP2017505350A
(en)
|
2014-02-12 |
2017-02-16 |
アミカス セラピューティックス インコーポレイテッド |
Sugar derivatives containing sulfur-containing moieties and methods for their preparation and methods of use for the treatment of MPS IIIC
|
EP3119415A4
(en)
|
2014-03-07 |
2017-11-29 |
The Arizona Board of Regents on behalf of the University of Arizona |
Non-narcotic crmp2 peptides targeting sodium channels for chronic pain
|
AU2015231413B2
(en)
|
2014-03-19 |
2020-04-23 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds for use in the treatment of PI3K-gamma mediated disorders
|
TWI687428B
(en)
|
2014-03-27 |
2020-03-11 |
中央研究院 |
Reactive labelling compounds and uses thereof
|
ES2868305T3
(en)
|
2014-03-28 |
2021-10-21 |
Univ Washington Through Its Center For Commercialization |
Vaccines against breast and ovarian cancer
|
US9675627B2
(en)
|
2014-04-14 |
2017-06-13 |
Amicus Therapeutics, Inc. |
Dosing regimens for treating and/or preventing cerebral amyloidoses
|
WO2015164614A1
(en)
|
2014-04-23 |
2015-10-29 |
Dana-Farber Cancer Institute, Inc. |
Janus kinase inhibitors and uses thereof
|
US9862688B2
(en)
|
2014-04-23 |
2018-01-09 |
Dana-Farber Cancer Institute, Inc. |
Hydrophobically tagged janus kinase inhibitors and uses thereof
|
WO2015168079A1
(en)
|
2014-04-29 |
2015-11-05 |
Infinity Pharmaceuticals, Inc. |
Pyrimidine or pyridine derivatives useful as pi3k inhibitors
|
US10039816B2
(en)
|
2014-04-30 |
2018-08-07 |
Massachusetts Institute Of Technology |
Siderophore-based immunization against gram-negative bacteria
|
US10029048B2
(en)
|
2014-05-13 |
2018-07-24 |
Allergan, Inc. |
High force injection devices
|
US10533039B2
(en)
|
2014-05-21 |
2020-01-14 |
President And Fellows Of Harvard College |
Ras inhibitory peptides and uses thereof
|
AU2015267045B2
(en)
|
2014-05-27 |
2021-02-25 |
Academia Sinica |
Anti-HER2 glycoantibodies and uses thereof
|
AU2015267052A1
(en)
|
2014-05-27 |
2016-12-15 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
KR20220151036A
(en)
|
2014-05-27 |
2022-11-11 |
아카데미아 시니카 |
Anti-cd20 glycoantibodies and uses thereof
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
US11332523B2
(en)
|
2014-05-28 |
2022-05-17 |
Academia Sinica |
Anti-TNF-alpha glycoantibodies and uses thereof
|
JP6612017B2
(en)
*
|
2014-06-03 |
2019-11-27 |
株式会社ダイセル |
Needleless syringe injection system
|
PE20170441A1
(en)
|
2014-06-06 |
2017-04-26 |
Bristol Myers Squibb Co |
ANTIBODIES AGAINST THE GLUCOCORTICOID-INDUCED TUMOR NECROSIS FACTOR RECEPTOR (GITR) AND ITS USES
|
CN107073109B
(en)
|
2014-06-11 |
2021-08-06 |
凯西·A·格林 |
Use of VISTA agonists and antagonists to inhibit or enhance humoral immunity
|
JP6664338B2
(en)
|
2014-06-13 |
2020-03-13 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
Immunogenic combination
|
MA40240B1
(en)
|
2014-06-19 |
2019-03-29 |
Ariad Pharma Inc |
Heteroaryl compounds of kinase inhibition
|
EP2959931A1
(en)
|
2014-06-24 |
2015-12-30 |
LTS LOHMANN Therapie-Systeme AG |
Needle-free injection device
|
US20170291939A1
(en)
|
2014-06-25 |
2017-10-12 |
Novartis Ag |
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
|
WO2015200425A1
(en)
|
2014-06-27 |
2015-12-30 |
Topokine Therapeutics, Inc. |
Topical dosage regimen
|
US9840479B2
(en)
|
2014-07-02 |
2017-12-12 |
Massachusetts Institute Of Technology |
Polyamine-fatty acid derived lipidoids and uses thereof
|
WO2016004197A1
(en)
|
2014-07-03 |
2016-01-07 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
|
WO2016007764A1
(en)
|
2014-07-09 |
2016-01-14 |
Abbvie Inc. |
Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
|
US9517307B2
(en)
|
2014-07-18 |
2016-12-13 |
Kaleo, Inc. |
Devices and methods for delivering opioid antagonists including formulations for naloxone
|
US10759836B2
(en)
|
2014-07-18 |
2020-09-01 |
University Of Washington |
Cancer vaccine compositions and methods of use thereof
|
AR101669A1
(en)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
ANTIBODY CONSTRUCTS FOR CDH19 AND CD3
|
AR101400A1
(en)
|
2014-07-31 |
2016-12-14 |
Amgen Res (Munich) Gmbh |
INDIVIDUAL CHAIN INDIVIDUAL CHAIN ANTIBODY CONSTRUCTION WITH IMPROVED FABRIC DISTRIBUTION
|
TW201609812A
(en)
|
2014-07-31 |
2016-03-16 |
安美基研究(慕尼黑)公司 |
Optimized cross-species specific bispecific single chain antibody constructs
|
EP2979714A1
(en)
|
2014-08-02 |
2016-02-03 |
LTS LOHMANN Therapie-Systeme AG |
Needleless injection device with a membrane
|
WO2016025331A1
(en)
|
2014-08-11 |
2016-02-18 |
University Of Massachusetts |
Anti-ospa antibodies and methods of use
|
WO2016025643A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Brush-poly(glycoamidoamine)-lipids and uses thereof
|
JO3663B1
(en)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
Anti-lag3 antibodies and antigen-binding fragments
|
UA122395C2
(en)
|
2014-08-19 |
2020-11-10 |
Мерк Шарп Енд Доум Корп. |
ANTIBODY AGAINST TIGIT
|
EP3185885B1
(en)
|
2014-08-26 |
2020-08-19 |
Compugen Ltd. |
Polypeptides and uses thereof as a drug for treatment of autoimmune disorders
|
CN107001404B
(en)
|
2014-09-08 |
2021-06-29 |
中央研究院 |
Activation of human iNKT cells using glycolipids
|
EP2993174A1
(en)
|
2014-09-08 |
2016-03-09 |
Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH |
Pyrazolopyridine derivatives and their use in therapy
|
CN112972378A
(en)
|
2014-09-24 |
2021-06-18 |
艾瑞朗医疗公司 |
Peptidomimetic macrocycles and formulations thereof
|
SG11201702223UA
(en)
|
2014-09-24 |
2017-04-27 |
Aileron Therapeutics Inc |
Peptidomimetic macrocycles and uses thereof
|
US10226585B2
(en)
|
2014-10-01 |
2019-03-12 |
Allergan, Inc. |
Devices for injection and dosing
|
EP3201226A2
(en)
|
2014-10-03 |
2017-08-09 |
Massachusetts Institute of Technology |
Antibodies that bind ebola glycoprotein and uses thereof
|
US9708348B2
(en)
|
2014-10-03 |
2017-07-18 |
Infinity Pharmaceuticals, Inc. |
Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
|
US9732119B2
(en)
|
2014-10-10 |
2017-08-15 |
Bristol-Myers Squibb Company |
Immunomodulators
|
KR102331856B1
(en)
|
2014-10-21 |
2021-11-29 |
다케다 야쿠힌 고교 가부시키가이샤 |
Crystalline forms of 5-chloro-n4-[2-(dimethylphosphoryl)phenyl]-n2-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]pyrimidine-2,4-diamine
|
EP3011988A1
(en)
|
2014-10-22 |
2016-04-27 |
LTS LOHMANN Therapie-Systeme AG |
Needle-free injection device with a gel and a membrane
|
JP2017533238A
(en)
|
2014-10-28 |
2017-11-09 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
Compositions and methods for antigen-specific tolerance
|
EP3041948B1
(en)
|
2014-11-10 |
2019-01-09 |
Modernatx, Inc. |
Alternative nucleic acid molecules containing reduced uracil content and uses thereof
|
EP3217982A1
(en)
|
2014-11-10 |
2017-09-20 |
Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death
|
US10077287B2
(en)
|
2014-11-10 |
2018-09-18 |
Bristol-Myers Squibb Company |
Tubulysin analogs and methods of making and use
|
US9856292B2
(en)
|
2014-11-14 |
2018-01-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
MX2017006323A
(en)
|
2014-11-21 |
2017-08-21 |
Bristol Myers Squibb Co |
Antibodies comprising modified heavy constant regions.
|
CN113773388A
(en)
|
2014-11-21 |
2021-12-10 |
百时美施贵宝公司 |
anti-CD 73 antibodies and uses thereof
|
US10253045B2
(en)
|
2014-11-26 |
2019-04-09 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of a therapeutic compound and uses thereof
|
EP3227341A1
(en)
|
2014-12-02 |
2017-10-11 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
|
EP3226900A4
(en)
|
2014-12-05 |
2018-09-19 |
Immunext, Inc. |
Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
|
EP3230272B1
(en)
|
2014-12-10 |
2020-08-19 |
Kala Pharmaceuticals, Inc. |
1-amino-triazolo(1,5-a)pyridine-substituted urea derivative and uses thereof
|
US9861680B2
(en)
|
2014-12-18 |
2018-01-09 |
Bristol-Myers Squibb Company |
Immunomodulators
|
CN113563468A
(en)
|
2014-12-19 |
2021-10-29 |
雷根尼桑斯公司 |
Antibodies that bind to human C6 and uses thereof
|
AU2015371251B2
(en)
|
2014-12-23 |
2020-06-11 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 (CDK7)
|
JP7358029B2
(en)
|
2014-12-23 |
2023-10-10 |
スローン - ケタリング・インスティテュート・フォー・キャンサー・リサーチ |
Granaticin B polymorphism
|
KR102644115B1
(en)
|
2014-12-23 |
2024-03-05 |
브리스톨-마이어스 스큅 컴퍼니 |
Antibodies to tigit
|
US10538596B2
(en)
|
2015-01-09 |
2020-01-21 |
Adalta Limited |
CXCR4 binding molecules and methods of use thereof
|
PE20171185A1
(en)
|
2015-01-14 |
2017-08-22 |
Bristol Myers Squibb Co |
BENZODIAZEPINE DIMERS UNITED WITH HETEROARYLENE BRIDGES, CONJUGATES OF THESE, AND THEIR METHODS OF PREPARATION AND USE
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
KR20170104617A
(en)
|
2015-01-24 |
2017-09-15 |
아카데미아 시니카 |
Novel glycan conjugates and methods for using them
|
US20160222060A1
(en)
|
2015-02-04 |
2016-08-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
WO2016127052A1
(en)
|
2015-02-05 |
2016-08-11 |
Bristol-Myers Squibb Company |
Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
|
WO2016144773A1
(en)
|
2015-03-06 |
2016-09-15 |
Abbvie Inc. |
Arabinosylated glycoproteins
|
EP3268037B1
(en)
|
2015-03-09 |
2022-08-31 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
CN107530490B
(en)
|
2015-03-10 |
2021-06-25 |
爱力根销售有限责任公司 |
Multi-needle syringe
|
US9809625B2
(en)
|
2015-03-18 |
2017-11-07 |
Bristol-Myers Squibb Company |
Immunomodulators
|
BR112017019738A2
(en)
|
2015-03-20 |
2018-05-29 |
Aileron Therapeutics Inc |
peptidomimetic macrocycles and their uses
|
US20180071380A1
(en)
|
2015-03-20 |
2018-03-15 |
The Regents Of The University Of Michigan |
Immunogenic compositions for use in vaccination against bordetella
|
CA2980004C
(en)
|
2015-03-24 |
2023-10-10 |
Kaleo, Inc. |
Devices and methods for delivering a lyophilized medicament
|
WO2016160617A2
(en)
|
2015-03-27 |
2016-10-06 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
JP6843065B2
(en)
|
2015-03-30 |
2021-03-17 |
グリーンライト バイオサイエンシーズ インコーポレーテッドGreenlight Biosciences,Inc. |
Cell-free production of ribonucleic acid
|
CA3232651A1
(en)
|
2015-04-02 |
2016-10-06 |
Intervet International B.V. |
Antibodies to canine interleukin-4 receptor alpha
|
UA126270C2
(en)
|
2015-04-10 |
2022-09-14 |
Емджен Інк. |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
RU2017130313A
(en)
|
2015-04-10 |
2019-05-13 |
Гельмгольц Центрум Мюнхен - Дойчес Форшунгсцентрум Фюр Гезундхайт Унд Умвельт (Гмбх) |
PYRONA DERIVATIVES FOR USE IN THERAPY
|
CN116063541A
(en)
|
2015-04-17 |
2023-05-05 |
安进研发(慕尼黑)股份有限公司 |
Bispecific antibody constructs for CDH3 and CD3
|
CN107708693A
(en)
|
2015-04-27 |
2018-02-16 |
佛罗里达大学研究基金会 |
Metal-chelator of Metabolic programming and application thereof
|
EP3288584A2
(en)
|
2015-04-30 |
2018-03-07 |
President and Fellows of Harvard College |
Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
|
WO2016178591A2
(en)
|
2015-05-05 |
2016-11-10 |
Gene Predit, Sa |
Genetic markers and treatment of male obesity
|
ES2962885T3
(en)
|
2015-05-15 |
2024-03-21 |
Massachusetts Gen Hospital |
Tumor necrosis factor receptor superfamily antagonist antibodies
|
US10568852B2
(en)
|
2015-05-22 |
2020-02-25 |
Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) |
Combination compositions and their use in methods for treating obesity and obesity-related disorders
|
WO2016189045A1
(en)
|
2015-05-27 |
2016-12-01 |
Ucb Biopharma Sprl |
Method for the treatment of neurological disease
|
WO2016196895A1
(en)
*
|
2015-06-05 |
2016-12-08 |
Joslin Diabetes Center, Inc. |
Methods amd compositions for promoting thermogenic potential
|
EP3307728A4
(en)
|
2015-06-12 |
2019-07-17 |
Dana Farber Cancer Institute, Inc. |
Combination therapy of transcription inhibitors and kinase inhibitors
|
CA3027884A1
(en)
*
|
2015-06-15 |
2016-12-22 |
Nuance Designs Of Ct, Llc |
Autoinjector
|
JP2017000667A
(en)
|
2015-06-16 |
2017-01-05 |
国立大学法人三重大学 |
Needle-free injector and method for introducing dna to injection target area using the same
|
CA2990172A1
(en)
|
2015-06-19 |
2016-12-22 |
Massachusetts Institute Of Technology |
Alkenyl substituted 2,5-piperazinediones and their use in compositions for delivering an agent to a subject or cell
|
WO2016207717A1
(en)
|
2015-06-24 |
2016-12-29 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments
|
JOP20200312A1
(en)
|
2015-06-26 |
2017-06-16 |
Novartis Ag |
Factor xi antibodies and methods of use
|
CN107922500A
(en)
|
2015-06-29 |
2018-04-17 |
洛克菲勒大学 |
The anti-CD 40 antibodies of agonist activity with enhancing
|
GB2556479B
(en)
|
2015-06-30 |
2022-09-07 |
Kaleo Inc |
Auto-injectors for administration of a medicament within a prefilled syringe
|
US10059741B2
(en)
|
2015-07-01 |
2018-08-28 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles
|
WO2017009712A1
(en)
|
2015-07-13 |
2017-01-19 |
Compugen Ltd. |
Hide1 compositions and methods
|
TWI717375B
(en)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for cd70 and cd3
|
TWI744242B
(en)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for egfrviii and cd3
|
TWI796283B
(en)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for msln and cd3
|
TW202346349A
(en)
|
2015-07-31 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for dll3 and cd3
|
TWI829617B
(en)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Antibody constructs for flt3 and cd3
|
JO3620B1
(en)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
Immune-checkpoint inhibitors for use in the treatment of blood-borne cancers cancers
|
US10179128B2
(en)
|
2015-08-31 |
2019-01-15 |
Amicus Therapeutics, Inc. |
Regimens for treating and preventing lysosomal disorders and degenerative disorders of the central nervous system
|
CA2996978A1
(en)
|
2015-09-09 |
2017-03-16 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
WO2017044633A1
(en)
|
2015-09-10 |
2017-03-16 |
Aileron Therapeutics, Inc. |
Peptidomimetic macrocycles as modulators of mcl-1
|
AU2016324310B2
(en)
|
2015-09-17 |
2021-04-08 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
EP3350333B1
(en)
|
2015-09-17 |
2021-10-27 |
ModernaTX, Inc. |
Polynucleotides containing a stabilizing tail region
|
RU2638457C2
(en)
|
2015-09-28 |
2017-12-13 |
Общество С Ограниченной Ответственностью "Онкомакс" |
Antibodies specifically binding type 1 receptor of fibroblast growth factor, antibodies application for oncological disease treatment, method for antibodies production
|
WO2017059132A1
(en)
|
2015-09-29 |
2017-04-06 |
The General Hospital Corporation |
Methods of treating and diagnosing disease using biomarkers for bcg therapy
|
JP6940853B2
(en)
|
2015-09-30 |
2021-09-29 |
リズム ファーマシューティカルズ, インコーポレイテッド |
How to treat melanocortin 4 receptor pathway-related disorders
|
US9925170B2
(en)
|
2015-10-01 |
2018-03-27 |
Kythera Biopharmaceuticals, Inc. |
Methods of adipolysis and compositions useful therein
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
JO3555B1
(en)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
Antibody neutralizing human respiratory syncytial virus
|
WO2017079768A1
(en)
|
2015-11-08 |
2017-05-11 |
Genentech, Inc. |
Methods of screening for multispecific antibodies
|
US10513553B2
(en)
|
2015-11-13 |
2019-12-24 |
Visterra, Inc. |
Compositions and methods for treating and preventing influenza
|
KR20180082563A
(en)
|
2015-11-19 |
2018-07-18 |
브리스톨-마이어스 스큅 컴퍼니 |
Antibodies to glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
|
UY36990A
(en)
|
2015-11-21 |
2017-11-30 |
Fundació Privada Inst De Recerca De La Sida-Caixa (Irsicaixa) |
DERIVATIVES OF ANTIBODIES AGAINST HIV WITH DUAL ANTIVIRAL AND IMMUNOMODULATORY ACTIVITY
|
EP3383903A1
(en)
|
2015-11-30 |
2018-10-10 |
Bristol-Myers Squibb Company |
Anti human ip-10 antibodies and their uses
|
WO2017095823A1
(en)
|
2015-11-30 |
2017-06-08 |
The Regents Of The University Of California |
Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
|
WO2017096432A1
(en)
|
2015-12-09 |
2017-06-15 |
Admedus Vaccines Pty Ltd |
Immunomodulating composition for treatment
|
JP7114465B2
(en)
|
2015-12-22 |
2022-08-08 |
モデルナティエックス インコーポレイテッド |
Compounds and compositions for intracellular delivery of drugs
|
RU2021129189A
(en)
|
2016-01-22 |
2021-11-15 |
Мерк Шарп И Доум Корп. |
ANTIBODIES AGAINST COAGULATION FACTOR XI
|
JOP20170017B1
(en)
|
2016-01-25 |
2021-08-17 |
Amgen Res Munich Gmbh |
Pharmaceutical composition comprising bispecific antibody constructs
|
EA039859B1
(en)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Bispecific antibody constructs binding egfrviii and cd3
|
WO2017134158A1
(en)
|
2016-02-03 |
2017-08-10 |
Amgen Research (Munich) Gmbh |
Psma and cd3 bispecific t cell engaging antibody constructs
|
DK3411402T3
(en)
|
2016-02-03 |
2022-02-07 |
Amgen Res Munich Gmbh |
BCMA AND CD3 BISPECIFIC T-CELL INVOLVING ANTIBODY CONSTRUCTIONS
|
MX2018009800A
(en)
|
2016-02-12 |
2018-11-09 |
Janssen Pharmaceutica Nv |
Anti-vista (b7h5) antibodies.
|
MA44236A
(en)
|
2016-02-17 |
2018-12-26 |
Novartis Ag |
ANTI-TGFBETA ANTIBODY 2
|
US20170240617A1
(en)
|
2016-02-24 |
2017-08-24 |
Visterra, Inc. |
Formulations of antibody molecules to influenza virus
|
IL307425A
(en)
|
2016-03-04 |
2023-12-01 |
Univ Rockefeller |
Antibodies to cd40 with enhanced agonist activity
|
US10143746B2
(en)
|
2016-03-04 |
2018-12-04 |
Bristol-Myers Squibb Company |
Immunomodulators
|
AU2017228470A1
(en)
|
2016-03-04 |
2018-08-30 |
Bristol-Myers Squibb Company |
Combination therapy with anti-CD73 antibodies
|
AU2017231749A1
(en)
|
2016-03-08 |
2018-09-20 |
Academia Sinica |
Methods for modular synthesis of N-glycans and arrays thereof
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
JP6910075B2
(en)
|
2016-03-28 |
2021-07-28 |
イコル メディカル システムズ,インク. |
Methods and devices for delivery of therapeutic agents
|
US10358463B2
(en)
|
2016-04-05 |
2019-07-23 |
Bristol-Myers Squibb Company |
Immunomodulators
|
CR20180525A
(en)
|
2016-04-06 |
2019-02-14 |
Greenlight Biosciences Inc |
RIBONUCLEIC ACID PRODUCTION FREE OF CELLS
|
KR102288170B1
(en)
|
2016-04-08 |
2021-08-09 |
알레간 인코포레이티드 |
Aspiration and injection device
|
EP3442579A4
(en)
|
2016-04-15 |
2019-12-18 |
Immunext Inc. |
Anti-human vista antibodies and use thereof
|
EA201892362A1
(en)
|
2016-04-18 |
2019-04-30 |
Селлдекс Терапьютикс, Инк. |
AGONISTIC ANTIBODIES THAT ARE BINDING HUMAN CD40, AND THEIR OPTIONS
|
WO2017184586A1
(en)
|
2016-04-18 |
2017-10-26 |
The Trustees Of Columbia University In The City Of New York |
Therapeutic targets involved in the progression of nonalcoholic steatohepatitis (nash)
|
JOP20170091B1
(en)
|
2016-04-19 |
2021-08-17 |
Amgen Res Munich Gmbh |
Administration of a bispecific construct binding to CD33 and CD3 for use in a method for the treatment of myeloid leukemia
|
BR112018069417A2
(en)
|
2016-04-22 |
2019-01-22 |
Biontech Rna Pharmaceuticals Gmbh |
method to provide simple ribbon and ssrna rna
|
WO2017190113A1
(en)
*
|
2016-04-29 |
2017-11-02 |
Altaviz, Llc |
Self-powered syringe
|
JP7422480B2
(en)
|
2016-05-04 |
2024-01-26 |
アムジエン・インコーポレーテツド |
Interleukin-2 mutant protein for regulatory T cell proliferation
|
EA039084B1
(en)
|
2016-05-09 |
2021-12-01 |
Бристол-Майерс Сквибб Компани |
Tl1a antibodies and uses thereof
|
TW201802121A
(en)
|
2016-05-25 |
2018-01-16 |
諾華公司 |
Reversal binding agents for anti-factor XI/XIa antibodies and uses thereof
|
JP7110119B2
(en)
|
2016-06-03 |
2022-08-01 |
サノフィ パスツール インコーポレイティッド |
Modifications of Engineered Influenza Hemagglutinin Polypeptides
|
US10105449B2
(en)
|
2016-06-07 |
2018-10-23 |
Massachusetts Institute Of Technology |
Drug delivery polymers and uses thereof
|
WO2017214269A1
(en)
|
2016-06-08 |
2017-12-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
WO2017218371A1
(en)
|
2016-06-14 |
2017-12-21 |
Merck Sharp & Dohme Corp. |
Anti-coagulation factor xi antibodies
|
WO2017218704A1
(en)
|
2016-06-14 |
2017-12-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
US20180002417A1
(en)
|
2016-06-15 |
2018-01-04 |
Celimmune Llc |
Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
US10328205B2
(en)
*
|
2016-07-07 |
2019-06-25 |
Shl Medical Ag |
Drug delivery device with pneumatic power pack
|
CN109757103B
(en)
|
2016-07-14 |
2024-01-02 |
百时美施贵宝公司 |
Antibodies against TIM3 and uses thereof
|
WO2018018082A1
(en)
|
2016-07-26 |
2018-02-01 |
The Australian National University |
Immunostimulatory compositions and uses therefor
|
US20180028755A1
(en)
|
2016-07-28 |
2018-02-01 |
Portal Instruments, Inc. |
Connected health platform including needle-free injector system
|
NL2017267B1
(en)
|
2016-07-29 |
2018-02-01 |
Aduro Biotech Holdings Europe B V |
Anti-pd-1 antibodies
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
EP3494141A4
(en)
|
2016-08-03 |
2020-04-08 |
Bio-Techne Corporation |
Identification of vsig3/vista as a novel immune checkpoint and use thereof for immunotherapy
|
WO2018027123A1
(en)
|
2016-08-05 |
2018-02-08 |
Sanofi Pasteur, Inc. |
Multivalent pneumococcal polysaccharide-protein conjugate composition
|
NL2017294B1
(en)
|
2016-08-05 |
2018-02-14 |
Univ Erasmus Med Ct Rotterdam |
Natural cryptic exon removal by pairs of antisense oligonucleotides.
|
BR112019001971A2
(en)
|
2016-08-05 |
2019-05-07 |
Sanofi Pasteur, Inc. |
multivalent pneumococcal polysaccharide-protein conjugate composition
|
JP7023933B2
(en)
|
2016-08-19 |
2022-02-22 |
ブリストル-マイヤーズ スクイブ カンパニー |
Seco-cyclopropyrroloindole compound, its antibody-drug conjugate, and how to make and use it.
|
CN109963868B
(en)
|
2016-08-22 |
2023-11-14 |
醣基生医股份有限公司 |
Antibodies, binding fragments, and methods of use
|
WO2018035710A1
(en)
|
2016-08-23 |
2018-03-01 |
Akeso Biopharma, Inc. |
Anti-ctla4 antibodies
|
WO2018044970A1
(en)
|
2016-08-31 |
2018-03-08 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
|
JOP20190055A1
(en)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
Anti-cd27 antibodies
|
EP3305781A1
(en)
|
2016-10-07 |
2018-04-11 |
Deutsches Krebsforschungszentrum |
Chemical substances which inhibit the enzymatic activity of human kallikrein-related peptidase 6 (klk6)
|
EP3525815A2
(en)
|
2016-10-13 |
2019-08-21 |
Massachusetts Institute of Technology |
Antibodies that bind zika virus envelope protein and uses thereof
|
JP7100030B2
(en)
|
2016-10-28 |
2022-07-12 |
アスチュート メディカル,インコーポレイテッド |
Use of antibody against TIMP-2 to improve renal function
|
KR102526034B1
(en)
|
2016-11-07 |
2023-04-25 |
브리스톨-마이어스 스큅 컴퍼니 |
immunomodulator
|
US11583504B2
(en)
|
2016-11-08 |
2023-02-21 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
WO2018089807A2
(en)
|
2016-11-11 |
2018-05-17 |
The Regents Of The University Of California |
Anti-cd46 antibodies and methods of use
|
KR20190077476A
(en)
|
2016-11-18 |
2019-07-03 |
뉴로바이브 파마슈티컬 에이비 |
Uses of phosglycerin macrocyclic analogs as anticancer compounds
|
WO2018106738A1
(en)
|
2016-12-05 |
2018-06-14 |
Massachusetts Institute Of Technology |
Brush-arm star polymers, conjugates and particles, and uses thereof
|
DK3478719T3
(en)
|
2016-12-21 |
2021-03-01 |
Mereo Biopharma 3 Ltd |
USE OF ANTI-SCLEROSTIN ANTIBODIES IN THE TREATMENT OF OSTEOGENESIS IMPERFECTA
|
WO2018115879A1
(en)
|
2016-12-21 |
2018-06-28 |
Mereo Biopharma 3 Limited |
Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
|
WO2018116255A1
(en)
|
2016-12-23 |
2018-06-28 |
Novartis Ag |
Factor xi antibodies and methods of use
|
EP3558420A4
(en)
|
2016-12-23 |
2020-05-27 |
Kaleo, Inc. |
Medicament delivery device and methods for delivering drugs to infants and children
|
CA3045043A1
(en)
|
2016-12-31 |
2018-07-05 |
Bioxcel Therapeutics, Inc. |
Use of sublingual dexmedetomidine for the treatment of agitation
|
ES2916217T3
(en)
|
2017-01-05 |
2022-06-29 |
Kahr Medical Ltd |
A SIRP1 ALPHA-41BBL fusion protein and methods of using the same
|
AU2018205888B2
(en)
|
2017-01-05 |
2021-09-02 |
Kahr Medical Ltd. |
A PD1-41BBL fusion protein and methods of use thereof
|
US20180244785A1
(en)
|
2017-01-09 |
2018-08-30 |
Merrimack Pharmaceuticals, Inc. |
Anti-fgfr antibodies and methods of use
|
WO2018136413A2
(en)
|
2017-01-17 |
2018-07-26 |
Kaleo, Inc. |
Medicament delivery devices with wireless connectivity and event detection
|
WO2018133873A1
(en)
|
2017-01-23 |
2018-07-26 |
苏州康宁杰瑞生物科技有限公司 |
Pd-l1 binding polypeptide or composite
|
WO2018140510A1
(en)
|
2017-01-25 |
2018-08-02 |
Biogen Ma Inc. |
Compositions and methods for treatment of stroke and other cns disorders
|
JOP20190189A1
(en)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
Low ph pharmaceutical composition comprising t cell engaging antibody constructs
|
GB2559553B
(en)
*
|
2017-02-06 |
2021-10-13 |
Consort Medical Plc |
A medicament delivery device
|
GB201702144D0
(en)
|
2017-02-09 |
2017-03-29 |
Annexin Pharmaceuticals Ab |
Therapeutic compositions
|
US20200131196A1
(en)
|
2017-02-10 |
2020-04-30 |
Mount Tam Therapeutics, Inc. |
Rapamycin Analog
|
CA3051839A1
(en)
|
2017-02-17 |
2018-08-23 |
Bristol-Myers Squibb Company |
Antibodies to alpha-synuclein and uses thereof
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
CA3055653A1
(en)
|
2017-03-15 |
2018-09-20 |
Modernatx, Inc. |
Lipid nanoparticle formulation
|
AU2018234692B2
(en)
|
2017-03-15 |
2022-06-02 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of therapeutic agents
|
US11555031B2
(en)
|
2017-03-20 |
2023-01-17 |
The Broad Institute, Inc. |
Compounds and methods for regulating insulin secretion
|
USD867582S1
(en)
|
2017-03-24 |
2019-11-19 |
Allergan, Inc. |
Syringe device
|
BR112019020810A2
(en)
|
2017-04-05 |
2020-04-28 |
Biogen Ma Inc |
tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof
|
TWI788340B
(en)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
Anti-icos agonist antibodies and uses thereof
|
TWI796329B
(en)
|
2017-04-07 |
2023-03-21 |
美商默沙東有限責任公司 |
Anti-ilt4 antibodies and antigen-binding fragments
|
EP3609922A2
(en)
|
2017-04-13 |
2020-02-19 |
Aduro Biotech Holdings, Europe B.V. |
Anti-sirp alpha antibodies
|
EP3615509A1
(en)
|
2017-04-25 |
2020-03-04 |
Amicus Therapeutics, Inc. |
Novel compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders
|
UY37726A
(en)
|
2017-05-05 |
2018-11-30 |
Amgen Inc |
PHARMACEUTICAL COMPOSITION THAT INCLUDES BISPECTIFIC ANTIBODY CONSTRUCTIONS FOR IMPROVED STORAGE AND ADMINISTRATION
|
WO2018207023A2
(en)
|
2017-05-10 |
2018-11-15 |
Albajuna Therapeutics, S.L. |
Fc-fusion protein derivatives with high dual hiv antiviral and immunomodulatory activity
|
US11168129B2
(en)
|
2017-05-15 |
2021-11-09 |
University Of Rochester |
Broadly neutralizing anti-influenza human monoclonal antibody and uses thereof
|
CN116333129A
(en)
|
2017-05-25 |
2023-06-27 |
百时美施贵宝公司 |
Antibodies comprising modified heavy chain constant regions
|
EP3638678A1
(en)
|
2017-06-14 |
2020-04-22 |
Modernatx, Inc. |
Compounds and compositions for intracellular delivery of agents
|
US11612647B2
(en)
|
2017-06-23 |
2023-03-28 |
University Of Maryland, Baltimore |
Immunogenic compositions
|
JP2020524527A
(en)
|
2017-06-23 |
2020-08-20 |
スージョウ ボジュホワ バイオメディカル デクノロジー カンパニー リミテッドSuzhou Bojuhua Biomedical Technology Co. Ltd |
Monoclonal antibodies targeting human tumor stem cells and uses thereof
|
US11066445B2
(en)
|
2017-06-23 |
2021-07-20 |
Bristol-Myers Squibb Company |
Immunomodulators acting as antagonists of PD-1
|
WO2019013789A1
(en)
|
2017-07-12 |
2019-01-17 |
Curza Global, Llc |
Antimicrobial compounds
|
WO2019013790A1
(en)
|
2017-07-12 |
2019-01-17 |
Curza Global, Llc |
Antimicrobial compounds and uses thereof
|
CN111201036A
(en)
|
2017-08-22 |
2020-05-26 |
比奥根Ma公司 |
Pharmaceutical compositions and dosage regimens comprising anti- α (V) β (6) antibodies
|
US11414450B1
(en)
|
2017-08-28 |
2022-08-16 |
Revagenix, Inc. |
Aminoglycosides and uses thereof
|
KR20200095455A
(en)
|
2017-08-28 |
2020-08-10 |
상하이 일레 바이오테크놀로지 씨오., 엘티디. |
Polypeptides and antibodies that bind to the polypeptide
|
MX2020002348A
(en)
|
2017-08-31 |
2020-10-08 |
Modernatx Inc |
Methods of making lipid nanoparticles.
|
KR20200058506A
(en)
|
2017-10-03 |
2020-05-27 |
브리스톨-마이어스 스큅 컴퍼니 |
Immunomodulators
|
SG11202003114UA
(en)
|
2017-10-04 |
2020-05-28 |
Amgen Inc |
Transthyretin immunoglobulin fusions
|
WO2019075090A1
(en)
|
2017-10-10 |
2019-04-18 |
Tilos Therapeutics, Inc. |
Anti-lap antibodies and uses thereof
|
CA3078726A1
(en)
|
2017-10-11 |
2019-04-18 |
Greenlight Biosciences, Inc. |
Methods and compositions for nucleoside triphosphate and ribonucleic acid production
|
JP7035299B2
(en)
|
2017-10-26 |
2022-03-15 |
イミューンオンコ バイオファーマシューティカルズ (シャンハイ) カンパニー リミテッド |
New recombinant fusion proteins, as well as their preparation and use
|
JP2021501801A
(en)
|
2017-11-01 |
2021-01-21 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
Immunostimulatory agonist antibody for use in the treatment of cancer
|
AR113696A1
(en)
|
2017-11-17 |
2020-06-03 |
Merck Sharp & Dohme |
SPECIFIC ANTIBODIES FOR IMMUNOGLOBULIN TYPE 3 (ILT3) SIMILAR TRANSCRIPT AND ITS USES
|
EP3717033A4
(en)
|
2017-12-01 |
2021-08-25 |
North Carolina State University |
Fibrin particles and methods of making the same
|
EP3724229A1
(en)
|
2017-12-11 |
2020-10-21 |
Amgen Inc. |
Continuous manufacturing process for bispecific antibody products
|
WO2019123375A1
(en)
|
2017-12-21 |
2019-06-27 |
Gliapharm Sa |
Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
|
US20200339591A1
(en)
|
2017-12-21 |
2020-10-29 |
Gliapharm Sa |
Compositions and methods of treatment for neurological disorders comprising a dementia
|
GB201721582D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
S aureus antigens and immunogenic compositions
|
US11406628B2
(en)
*
|
2017-12-21 |
2022-08-09 |
Taiwan Liposome Co., Ltd |
Sustained-release triptan compositions and method of use the same through subdermal route or the like
|
GB201721576D0
(en)
|
2017-12-21 |
2018-02-07 |
Glaxosmithkline Biologicals Sa |
Hla antigens and glycoconjugates thereof
|
WO2019133747A1
(en)
|
2017-12-27 |
2019-07-04 |
Bristol-Myers Squibb Company |
Anti-cd40 antibodies and uses thereof
|
UY38041A
(en)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
CONSTRUCTION OF BIESPECFIC ANTIBODY DIRECTED TO MUC17 AND CD3
|
US20220089720A1
(en)
|
2018-01-12 |
2022-03-24 |
Bristol-Myers Squibb Company |
Antibodies against tim3 and uses thereof
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
CN111868082A
(en)
|
2018-02-02 |
2020-10-30 |
博奥泰克尼公司 |
Compounds that modulate the interaction of VISTA and VSIG3 and methods of making and using the same
|
KR101859735B1
(en)
|
2018-02-07 |
2018-05-21 |
주식회사 피테크 |
Painless injection device
|
WO2019157340A1
(en)
|
2018-02-08 |
2019-08-15 |
Amgen Inc. |
Low ph pharmaceutical antibody formulation
|
NL2020520B1
(en)
|
2018-03-02 |
2019-09-12 |
Labo Bio Medical Invest B V |
Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
|
BR112020026125A8
(en)
|
2018-03-15 |
2022-10-18 |
Biontech Rna Pharmaceuticals Gmbh |
SUPERIOR OLIGONUCLEOTIDE OR 5'-CAP-TRINUCLEOTIDE COMPOUNDS AND THEIR USES IN RNA STABILIZATION, PROTEIN EXPRESSION AND IN THERAPY
|
AU2019236865A1
(en)
|
2018-03-23 |
2020-10-01 |
Bristol-Myers Squibb Company |
Antibodies against MICA and/or MICB and uses thereof
|
WO2019184920A1
(en)
|
2018-03-26 |
2019-10-03 |
上海易乐生物技术有限公司 |
Use of probdnf regulator in b cell-related diseases
|
SG11202009625WA
(en)
|
2018-04-02 |
2020-10-29 |
Bristol Myers Squibb Co |
Anti-trem-1 antibodies and uses thereof
|
US11673907B2
(en)
|
2018-04-03 |
2023-06-13 |
Revagenix, Inc. |
Modular synthesis of aminoglycosides
|
AU2019249255A1
(en)
|
2018-04-06 |
2020-11-05 |
Alastair GARFIELD |
Compositions for treating kidney disease
|
WO2019200256A1
(en)
|
2018-04-12 |
2019-10-17 |
Bristol-Myers Squibb Company |
Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
|
SG11202010011RA
(en)
|
2018-04-17 |
2020-11-27 |
Celldex Therapeutics Inc |
Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
|
EP3781206A2
(en)
|
2018-04-20 |
2021-02-24 |
iOmx Therapeutics AG |
A 5-thiazolecarboxamide kinase inhibitor and uses thereof
|
KR102104080B1
(en)
*
|
2018-05-02 |
2020-04-23 |
주식회사 피테크 |
Sonic vibration device for painless syringe and painless sylinge having the same
|
KR102107578B1
(en)
*
|
2018-05-02 |
2020-05-07 |
주식회사 피테크 |
Constant velocity infusion device for painless syringe and painless sylinge having the same
|
US11958895B2
(en)
|
2018-05-03 |
2024-04-16 |
University Of Rochester |
Anti-influenza neuraminidase monoclonal antibodies and uses thereof
|
KR101907552B1
(en)
|
2018-05-03 |
2018-10-12 |
주식회사 피테크 |
Painless injection device without needle
|
US11059824B2
(en)
|
2018-05-25 |
2021-07-13 |
Primmune Therapeutics, Inc. |
Substituted purines as TLR7 agonists
|
KR20210027352A
(en)
|
2018-06-04 |
2021-03-10 |
바이오젠 엠에이 인코포레이티드 |
Anti-VLA-4 antibody with reduced effector function
|
US11951286B2
(en)
*
|
2018-06-12 |
2024-04-09 |
Banza Stamping Industry Corp. |
Automatic injection device for fluid
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
KR20210040945A
(en)
|
2018-06-21 |
2021-04-14 |
유마니티 테라퓨틱스, 인크. |
Composition and method for the treatment and prevention of neurological disorders
|
JP2021529756A
(en)
|
2018-06-27 |
2021-11-04 |
バイオエクセル セラピューティクス,インコーポレイテッド |
Film preparation containing dexmedetomidine and its preparation method
|
CN112543773A
(en)
|
2018-07-11 |
2021-03-23 |
卡尔医学有限公司 |
SIRP alpha-4-1 BBL variant fusion proteins and methods of use thereof
|
WO2020018433A1
(en)
|
2018-07-16 |
2020-01-23 |
Kaleo, Inc. |
Medicament delivery devices with wireless connectivity and compliance detection
|
MX2021001221A
(en)
|
2018-07-30 |
2021-06-23 |
Amgen Res Munich Gmbh |
Prolonged administration of a bispecific antibody construct binding to cd33 and cd3.
|
JP7412409B2
(en)
|
2018-07-31 |
2024-01-12 |
アムジェン インコーポレイテッド |
Pharmaceutical formulations of masked antibodies
|
TW202019477A
(en)
|
2018-07-31 |
2020-06-01 |
德商安美基研究(慕尼黑)公司 |
Dosing regimen for bcmaxcd3 antibody constructs
|
KR20210042117A
(en)
|
2018-08-03 |
2021-04-16 |
암젠 리서치 (뮌헨) 게엠베하 |
Antibody constructs against CLDN18.2 and CD3
|
CN112533954A
(en)
|
2018-08-08 |
2021-03-19 |
宜明昂科生物医药技术(上海)有限公司 |
Recombinant bifunctional protein targeting CD47 and HER2
|
WO2020049208A1
(en)
|
2018-09-09 |
2020-03-12 |
Fundacio Privada Institut De Recerca De La Sida - Caixa |
Aurora kinase as target for treating, preventing or curing hiv infection or aids
|
US20210371537A1
(en)
|
2018-09-18 |
2021-12-02 |
Merrimack Pharmaceuticals, Inc. |
Anti-tnfr2 antibodies and uses thereof
|
JP7410135B2
(en)
|
2018-09-19 |
2024-01-09 |
モデルナティエックス インコーポレイテッド |
Compounds and compositions for intracellular delivery of therapeutic agents
|
WO2020061457A1
(en)
|
2018-09-20 |
2020-03-26 |
Modernatx, Inc. |
Preparation of lipid nanoparticles and methods of administration thereof
|
KR102199724B1
(en)
*
|
2018-10-05 |
2021-01-07 |
주식회사 피테크 |
Painless injection device without needle
|
WO2020076969A2
(en)
|
2018-10-10 |
2020-04-16 |
Tilos Therapeutics, Inc. |
Anti-lap antibody variants and uses thereof
|
AU2019356564A1
(en)
|
2018-10-11 |
2021-04-29 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
US20220024944A1
(en)
|
2018-10-23 |
2022-01-27 |
Myelopro Diagnostics And Research Gmbh |
Compounds targeting mutant calreticulin
|
EP3643713A1
(en)
|
2018-10-23 |
2020-04-29 |
iOmx Therapeutics AG |
Heterocyclic kinase inhibitors and uses thereof
|
US11160791B2
(en)
|
2018-11-01 |
2021-11-02 |
Medefil, Inc. |
Dexmedetomidine injection premix formulation in ready to use (RTU) bags
|
EP3876989A4
(en)
|
2018-11-09 |
2022-12-07 |
University of Massachusetts |
Anti-cfae antibodies and methods of use
|
JP2022509942A
(en)
|
2018-11-16 |
2022-01-25 |
ブリストル-マイヤーズ スクイブ カンパニー |
Anti-NKG2A antibody and its use
|
WO2020112781A1
(en)
|
2018-11-28 |
2020-06-04 |
Bristol-Myers Squibb Company |
Antibodies comprising modified heavy constant regions
|
WO2020118011A1
(en)
|
2018-12-06 |
2020-06-11 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
JP2022512346A
(en)
|
2018-12-18 |
2022-02-03 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Compositions and Methods for Gaining Body Weight and Lean Body Mass Using Antagonists for Leptin Receptor, GDF8, and Activin A
|
TW202039554A
(en)
|
2018-12-19 |
2020-11-01 |
瑞士商諾華公司 |
Anti-tnf-alpha antibodies
|
WO2020132378A2
(en)
|
2018-12-22 |
2020-06-25 |
Gliapharm Sa |
Compositions and methods of treatment for neurological disorders comprising depression
|
WO2020144535A1
(en)
|
2019-01-08 |
2020-07-16 |
Aduro Biotech Holdings, Europe B.V. |
Methods and compositions for treatment of multiple myeloma
|
US20230072397A1
(en)
|
2019-01-16 |
2023-03-09 |
Curza Global, Llc |
Antimicrobial Compounds and Methods
|
CN113924292A
(en)
|
2019-01-16 |
2022-01-11 |
库扎环球有限责任公司 |
Antimicrobial compounds and methods
|
CN109762067B
(en)
|
2019-01-17 |
2020-02-28 |
北京天广实生物技术股份有限公司 |
Antibodies that bind human Claudin18.2 and uses thereof
|
EP3914291A2
(en)
|
2019-01-22 |
2021-12-01 |
F. Hoffmann-La Roche AG |
Immunoglobulin a antibodies and methods of production and use
|
WO2020154293A1
(en)
|
2019-01-22 |
2020-07-30 |
Bristol-Myers Squibb Company |
Antibodies against il-7r alpha subunit and uses thereof
|
EP3914245A4
(en)
|
2019-01-22 |
2022-08-24 |
Aeovian Pharmaceuticals, Inc. |
Mtorc modulators and uses thereof
|
CA3128215A1
(en)
|
2019-01-31 |
2020-08-06 |
Modernatx, Inc. |
Methods of preparing lipid nanoparticles
|
WO2020168466A1
(en)
|
2019-02-19 |
2020-08-27 |
Stemirna Therapeutics Co., Ltd. |
Modified nucleoside and synthetic methods thereof
|
CA3131953A1
(en)
|
2019-03-01 |
2020-09-10 |
Merrimack Pharmaceuticals, Inc. |
Anti-tnfr2 antibodies and uses thereof
|
JP2022524814A
(en)
|
2019-03-11 |
2022-05-10 |
バイオジェン・エムエイ・インコーポレイテッド |
Pharmaceutical composition comprising anti-LINGO-1 antibody
|
CA3132521A1
(en)
|
2019-03-25 |
2020-10-01 |
Visterra, Inc. |
Compositions and methods for treating and preventing influenza
|
MX2021012160A
(en)
|
2019-04-08 |
2022-01-06 |
Biogen Ma Inc |
Anti-integrin antibodies and uses thereof.
|
JP2022533233A
(en)
|
2019-05-21 |
2022-07-21 |
ブリストル-マイヤーズ スクイブ カンパニー |
Immunomodulator
|
EA202192810A1
(en)
|
2019-06-11 |
2022-03-05 |
Регенерон Фармасьютикалз, Инк. |
ANTIBODIES TO PcrV THAT BIND PcrV, COMPOSITIONS CONTAINING ANTIBODIES TO PcrV AND METHODS OF THEIR APPLICATION
|
AU2020290573A1
(en)
|
2019-06-13 |
2021-11-04 |
Amgen Inc. |
Automated biomass-based perfusion control in the manufacturing of biologics
|
SG11202112762TA
(en)
|
2019-07-08 |
2021-12-30 |
Amgen Inc |
Multispecific transthyretin immunoglobulin fusions
|
US20220267409A1
(en)
|
2019-07-11 |
2022-08-25 |
Kahr Medical Ltd. |
Heterodimers and methods of use thereof
|
EP3999539A1
(en)
|
2019-07-15 |
2022-05-25 |
Intervet International B.V. |
Caninized antibodies to human and canine ctla-4
|
JP2022540904A
(en)
|
2019-07-15 |
2022-09-20 |
ブリストル-マイヤーズ スクイブ カンパニー |
Antibodies against human TREM-1 and uses thereof
|
JP2022542808A
(en)
|
2019-07-15 |
2022-10-07 |
インターベット インターナショナル ベー. フェー. |
Caninized Antibodies Against Canine CTLA-4
|
WO2021011678A1
(en)
|
2019-07-15 |
2021-01-21 |
Bristol-Myers Squibb Company |
Anti-trem-1 antibodies and uses thereof
|
AU2020316013A1
(en)
|
2019-07-19 |
2022-02-17 |
Arx, Llc |
Non-sedating dexmedetomidine treatment regimens
|
KR20220042378A
(en)
|
2019-07-31 |
2022-04-05 |
사노피 파스퇴르 인코포레이티드 |
Polyvalent pneumococcal polysaccharide-protein conjugate composition and method of use thereof
|
JP2022543773A
(en)
|
2019-07-31 |
2022-10-14 |
モデルナティエックス インコーポレイテッド |
Compositions and methods for delivery of RNA interfering agents to immune cells
|
JP2022543523A
(en)
*
|
2019-08-09 |
2022-10-13 |
カレオ,インコーポレイテッド |
Device and method for delivery of substances in pre-filled syringes
|
CA3150441A1
(en)
|
2019-08-13 |
2021-02-18 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
JP2022547305A
(en)
|
2019-09-13 |
2022-11-11 |
ラトガース,ザ ステート ユニバーシティ オブ ニュー ジャージー |
AAV compatible laminin-linker polymeric protein
|
US20220389061A1
(en)
|
2019-10-30 |
2022-12-08 |
Bristol-Myers Squibb Company |
Immunomodulators
|
EP3819007A1
(en)
|
2019-11-11 |
2021-05-12 |
Amgen Research (Munich) GmbH |
Dosing regimen for anti-bcma agents
|
JP2023501575A
(en)
|
2019-11-13 |
2023-01-18 |
カーザ グローバル, エルエルシー |
Antimicrobial compounds and methods
|
AU2020381536A1
(en)
|
2019-11-13 |
2022-04-21 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
US20230022400A1
(en)
|
2019-11-19 |
2023-01-26 |
Bristol-Myers Squibb Company |
Immunomodulators
|
WO2021119467A1
(en)
|
2019-12-11 |
2021-06-17 |
Visterra, Inc. |
Compositions and methods for treating and preventing influenza
|
AU2020407208A1
(en)
|
2019-12-17 |
2022-06-02 |
Amgen Inc. |
Dual interleukin-2 /tnf receptor agonist for use in therapy
|
UY38995A
(en)
|
2019-12-20 |
2021-06-30 |
Amgen Inc |
MESOTHELIN TARGETING CD40 AGONIST MULTI-SPECIFIC ANTIBODY CONSTRUCTS FOR THE TREATMENT OF SOLID TUMORS
|
WO2021123094A1
(en)
|
2019-12-20 |
2021-06-24 |
Intervet International B.V. |
Bispecific caninized antibodies and bispecific binding partners for treating atopic dermatitis
|
CN114929746A
(en)
|
2019-12-20 |
2022-08-19 |
英特维特国际股份有限公司 |
Canine interleukin-4 receptor alpha antibodies
|
US20230065827A1
(en)
|
2020-01-06 |
2023-03-02 |
Bristol-Myers Squibb Company |
Immunomodulators
|
KR20220122751A
(en)
|
2020-01-06 |
2022-09-02 |
브리스톨-마이어스 스큅 컴퍼니 |
Macrocyclic Peptides as PD-L1 Inhibitors and Immunomodulators for the Treatment of Cancer and Infectious Diseases
|
CN110818795B
(en)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
anti-TIGIT antibodies and methods of use
|
EP4093771A1
(en)
|
2020-01-22 |
2022-11-30 |
Amgen Research (Munich) GmbH |
Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
|
TW202139976A
(en)
|
2020-01-31 |
2021-11-01 |
美商現代公司 |
Methods of preparing lipid nanoparticles
|
TW202140564A
(en)
|
2020-02-27 |
2021-11-01 |
大陸商正大天晴藥業集團股份有限公司 |
Antibodies binding il4r and uses thereof
|
WO2021173965A1
(en)
|
2020-02-28 |
2021-09-02 |
Massachusetts Institute Of Technology |
Identification of variable influenza residues and uses thereof
|
WO2021183428A1
(en)
|
2020-03-09 |
2021-09-16 |
Bristol-Myers Squibb Company |
Antibodies to cd40 with enhanced agonist activity
|
WO2021188480A1
(en)
|
2020-03-16 |
2021-09-23 |
Bristol-Myers Squibb Company |
Immunomodulators
|
JP2023518225A
(en)
|
2020-03-19 |
2023-04-28 |
アムジエン・インコーポレーテツド |
Antibodies against mucin 17 and uses thereof
|
WO2021195089A1
(en)
|
2020-03-23 |
2021-09-30 |
Sorrento Therapeutics, Inc. |
Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof
|
US20230151059A1
(en)
|
2020-03-30 |
2023-05-18 |
Bristol-Myers Squibb Company |
Immunomodulators
|
CA3170570A1
(en)
|
2020-04-01 |
2021-10-07 |
James J. KOBIE |
Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
|
WO2021207449A1
(en)
|
2020-04-09 |
2021-10-14 |
Merck Sharp & Dohme Corp. |
Affinity matured anti-lap antibodies and uses thereof
|
EP3901151A1
(en)
|
2020-04-21 |
2021-10-27 |
iOmx Therapeutics AG |
Halogenated-heteroaryl and other heterocyclic kinase inhibitors, and uses thereof
|
EP4139341A1
(en)
|
2020-04-21 |
2023-03-01 |
Regeneron Pharmaceuticals, Inc. |
Il-2 variants with reduced binding to il-2 receptor alpha and uses thereof
|
SG11202112792WA
(en)
|
2020-04-28 |
2021-12-30 |
Univ Rockefeller |
Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
|
US20230192701A1
(en)
|
2020-04-28 |
2023-06-22 |
Iomx Therapeutics Ag |
Bicyclic kinase inhibitors and uses thereof
|
JP2023524444A
(en)
|
2020-04-29 |
2023-06-12 |
アムジェン インコーポレイテッド |
Pharmaceutical formulation
|
CA3173934A1
(en)
|
2020-04-29 |
2021-11-04 |
Twinkle R. Christian |
Pharmaceutical formulation
|
WO2021219871A2
(en)
|
2020-04-30 |
2021-11-04 |
Aduro Biotech Holdings, Europe B.V. |
Anti-cd103 antibodies
|
WO2021226460A1
(en)
|
2020-05-08 |
2021-11-11 |
Bristol-Myers Squibb Company |
Immunomodulators
|
WO2021231729A1
(en)
|
2020-05-13 |
2021-11-18 |
Sanofi |
Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza
|
WO2021231732A1
(en)
|
2020-05-15 |
2021-11-18 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
CA3183756A1
(en)
|
2020-05-19 |
2021-11-25 |
Amgen Inc. |
Mageb2 binding constructs
|
US20230277524A1
(en)
|
2020-05-22 |
2023-09-07 |
Trailhead Biosystems Inc. |
Combination therapy for treatment of viral infections
|
CA3183693A1
(en)
|
2020-05-29 |
2021-12-02 |
Amgen Inc. |
Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3
|
WO2021252708A1
(en)
|
2020-06-11 |
2021-12-16 |
President And Fellows Of Harvard College |
Stabilized trioxacarcin antibody drug conjugates and uses thereof
|
FR3112939B1
(en)
|
2020-07-31 |
2024-01-05 |
Univ Montpellier |
Universal cell therapy product and its use
|
CN116419747A
(en)
|
2020-08-07 |
2023-07-11 |
福蒂斯治疗公司 |
CD46 targeting immunoconjugates and methods of use thereof
|
US20230348596A1
(en)
|
2020-08-24 |
2023-11-02 |
Amgen Inc. |
Pharmaceutical formulation
|
EP4221841A1
(en)
|
2020-10-02 |
2023-08-09 |
Bristol-Myers Squibb Company |
Macrocyclic peptide boronate immunomodulators
|
JP2023546020A
(en)
|
2020-10-08 |
2023-11-01 |
ブリストル-マイヤーズ スクイブ カンパニー |
Novel dimeric immunomodulator
|
CN116323640A
(en)
|
2020-10-09 |
2023-06-23 |
百时美施贵宝公司 |
Macrocyclic immunomodulators
|
EP4229083A1
(en)
|
2020-10-15 |
2023-08-23 |
Intervet International B.V. |
Caninized antibodies to canine interleukin-31 receptor alpha
|
JPWO2022092294A1
(en)
|
2020-10-30 |
2022-05-05 |
|
|
JPWO2022092295A1
(en)
|
2020-10-30 |
2022-05-05 |
|
|
WO2022098870A1
(en)
|
2020-11-04 |
2022-05-12 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
KR20230098334A
(en)
|
2020-11-06 |
2023-07-03 |
암젠 리서치 (뮌헨) 게엠베하 |
Polypeptide constructs that selectively bind to CLDN6 and CD3
|
CN116323671A
(en)
|
2020-11-06 |
2023-06-23 |
安进公司 |
Multi-targeting bispecific antigen binding molecules with increased selectivity
|
EP4240767A1
(en)
|
2020-11-06 |
2023-09-13 |
Amgen Inc. |
Polypeptide constructs binding to cd3
|
EP4240407A1
(en)
|
2020-11-06 |
2023-09-13 |
Amgen Inc. |
Antigen binding domain with reduced clipping rate
|
EP4243936A1
(en)
|
2020-11-10 |
2023-09-20 |
Amgen Inc. |
Methods for administering a bcma x cd3 binding molecule
|
WO2022101358A1
(en)
|
2020-11-11 |
2022-05-19 |
BioNTech SE |
Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
|
AR124267A1
(en)
|
2020-12-09 |
2023-03-01 |
Genentech Inc |
HIGH THROUGH METHODS FOR PREPARING LIPID NANOPARTICLES AND THEIR USES
|
DE102020134181A1
(en)
|
2020-12-18 |
2022-06-23 |
Henke-Sass, Wolf Gmbh |
Device for applying a fluid
|
CN114685669A
(en)
|
2020-12-30 |
2022-07-01 |
和铂医药(苏州)有限公司 |
Antibodies that bind TROP2 and uses thereof
|
EP4277926A1
(en)
|
2021-01-15 |
2023-11-22 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
WO2022192176A1
(en)
|
2021-03-09 |
2022-09-15 |
Massachusetts Institute Of Technology |
Branched poly(-amino esters) for the delivery of nucleic acids
|
KR20230169968A
(en)
|
2021-03-12 |
2023-12-18 |
브리스톨-마이어스 스큅 컴퍼니 |
KRAS inhibitors
|
CN117157306A
(en)
|
2021-03-24 |
2023-12-01 |
百时美施贵宝公司 |
Immunomodulators
|
JP2024515560A
(en)
|
2021-04-09 |
2024-04-10 |
セルデックス セラピューティクス インコーポレイテッド |
Antibodies to ILT4, bispecific anti-ILT4/PD-L1 antibodies, and methods of use thereof
|
JP2024516369A
(en)
|
2021-04-12 |
2024-04-15 |
ブリストル-マイヤーズ スクイブ カンパニー |
Cyclic peptide immunomodulators
|
EP4334343A2
(en)
|
2021-05-06 |
2024-03-13 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
IL307672A
(en)
|
2021-05-06 |
2023-12-01 |
Amgen Res Munich Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
AU2022268916A1
(en)
|
2021-05-06 |
2023-11-09 |
Amgen Inc. |
Etelcalcetide formulations
|
IL308282A
(en)
|
2021-05-10 |
2024-01-01 |
Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd |
Pharmaceutical compositions for treating neurological conditions
|
KR20240013732A
(en)
|
2021-05-26 |
2024-01-30 |
옥스포드 바이오테라퓨틱스 리미티드 |
Pharmaceutical combination comprising an anti-CD205 antibody and an immune checkpoint inhibitor
|
TW202313065A
(en)
|
2021-05-28 |
2023-04-01 |
美商季卡尼醫療公司 |
Compounds for treating genetic diseases
|
CA3217100A1
(en)
|
2021-06-09 |
2022-12-15 |
Gerald BURGSTALLER |
Novel anti-fibrotic drugs
|
WO2022261161A1
(en)
|
2021-06-09 |
2022-12-15 |
Bristol-Myers Squibb Company |
Cyclic peptide immunomodulators
|
IL308847A
(en)
|
2021-06-30 |
2024-01-01 |
Amgen Inc |
Method of reconstituting lyophilized formulation
|
WO2023288213A1
(en)
|
2021-07-12 |
2023-01-19 |
Bristol-Myers Squibb Company |
Macrocyclic immunomodulators
|
WO2023004240A1
(en)
|
2021-07-19 |
2023-01-26 |
Bristol-Myers Squibb Company |
Macrocylic immunomodulators
|
AU2022316209A1
(en)
|
2021-07-20 |
2024-02-22 |
Regeneron Pharmaceuticals, Inc. |
Butyrophilin-like 2 agents for treating inflammatory disorders
|
CN113398365B
(en)
*
|
2021-07-21 |
2022-10-28 |
南京瑞淇卓越医疗美容诊所有限公司 |
Clinical radiography injection device and injection method for cardiovascular medicine
|
WO2023018817A1
(en)
|
2021-08-11 |
2023-02-16 |
Sanofi Pasteur Inc. |
Truncated influenza neuraminidase and methods of using the same
|
WO2023021170A2
(en)
|
2021-08-20 |
2023-02-23 |
Intervet International B.V. |
Fusion proteins for treating atopic dermatitis
|
CA3227716A1
(en)
|
2021-08-20 |
2023-02-23 |
Intervet International B.V. |
Antibodies and igg fusion proteins with an extended half-life
|
WO2023039108A1
(en)
|
2021-09-08 |
2023-03-16 |
Affinivax, Inc. |
Coronavirus vaccine
|
CN113773401B
(en)
|
2021-09-15 |
2023-06-20 |
宜明昂科生物医药技术(上海)股份有限公司 |
Recombinant fusion protein targeting CD47 and PD-L1 and preparation and application thereof
|
TW202333778A
(en)
|
2021-10-08 |
2023-09-01 |
美商賽諾菲巴斯德公司 |
Multivalent influenza vaccines
|
CN113831412B
(en)
|
2021-10-13 |
2023-06-20 |
宜明昂科生物医药技术(上海)股份有限公司 |
Antibodies targeting CD24, their preparation and use
|
CN113754769B
(en)
|
2021-10-13 |
2023-06-06 |
宜明昂科生物医药技术(上海)股份有限公司 |
CD 70-targeting antibodies, their preparation and use
|
CN113956363B
(en)
|
2021-10-13 |
2023-03-31 |
宜明昂科生物医药技术(上海)股份有限公司 |
Recombinant fusion protein targeting CD47 and CD24 and preparation and application thereof
|
WO2023069994A1
(en)
|
2021-10-20 |
2023-04-27 |
Bristol-Myers Squibb Company |
Immunomodulators
|
TW202334221A
(en)
|
2021-11-03 |
2023-09-01 |
德商安富美德有限公司 |
Bispecific cd16a binders
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
WO2023079113A1
(en)
|
2021-11-05 |
2023-05-11 |
Sanofi |
Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same
|
WO2023081798A1
(en)
|
2021-11-05 |
2023-05-11 |
Sanofi Pasteur Inc. |
Multivalent influenza vaccines comprising recombinant hemagglutinin and neuraminidase and methods of using the same
|
WO2023077521A1
(en)
|
2021-11-08 |
2023-05-11 |
Celldex Therapeutics, Inc |
Anti-ilt4 and anti-pd-1 bispecific constructs
|
WO2023089314A1
(en)
|
2021-11-18 |
2023-05-25 |
Oxford Biotherapeutics Limited |
Pharmaceutical combinations
|
WO2023096904A2
(en)
|
2021-11-24 |
2023-06-01 |
President And Fellows Of Harvard College |
C-16 modified trioxacarcins, antibody drug conjugates, and uses thereof
|
WO2023102507A1
(en)
|
2021-12-03 |
2023-06-08 |
Bristol-Myers Squibb Company |
Macrocyclic immunomodulators
|
WO2023105281A1
(en)
|
2021-12-11 |
2023-06-15 |
Fundaciò Privada Institut De Recerca De La Sida-Caixa |
Soluble tigit recombinant proteins
|
WO2023114884A2
(en)
|
2021-12-15 |
2023-06-22 |
Interius Biotherapeutics, Inc. |
Pseudotyped viral particles, compositions comprising the same, and uses thereof
|
WO2023111148A1
(en)
|
2021-12-16 |
2023-06-22 |
Intervet International B.V. |
Caninized antibodies to canine interleukin-31 receptor alpha 1
|
TW202333654A
(en)
|
2021-12-16 |
2023-09-01 |
美商現代公司 |
Processes for preparing lipid nanoparticles
|
WO2023111157A1
(en)
|
2021-12-16 |
2023-06-22 |
Intervet International B.V. |
Caninized and felinized antibodies to human ngf
|
WO2023129963A1
(en)
|
2021-12-30 |
2023-07-06 |
Curza Global, Llc |
Antimicrobial compounds and methods
|
WO2023144206A1
(en)
|
2022-01-27 |
2023-08-03 |
Sanofi Pasteur |
Modified vero cells and methods of using the same for virus production
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
WO2023166488A1
(en)
|
2022-03-04 |
2023-09-07 |
Revagenix, Inc. |
Broad spectrum aminoglycosides and uses thereof
|
WO2023177577A1
(en)
|
2022-03-14 |
2023-09-21 |
Sanofi Pasteur Inc. |
Machine-learning techniques in protein design for vaccine generation
|
WO2023175171A1
(en)
|
2022-03-18 |
2023-09-21 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Bk polyomavirus antibodies and uses thereof
|
WO2023192873A1
(en)
|
2022-03-28 |
2023-10-05 |
Bristol-Myers Squibb Company |
Macrocyclic immunomodulators
|
WO2023193002A1
(en)
|
2022-04-01 |
2023-10-05 |
Modernatx, Inc. |
Cross mixers for lipid nanoparticle production, and methods of operating the same
|
EP4257609A1
(en)
|
2022-04-08 |
2023-10-11 |
iOmx Therapeutics AG |
Combination therapies based on pd-1 inhibitors and sik3 inhibitors
|
EP4257132A1
(en)
|
2022-04-08 |
2023-10-11 |
iOmx Therapeutics AG |
Sik3 inhibitors for treating diseases resistant to death receptor signalling
|
WO2023212559A1
(en)
|
2022-04-26 |
2023-11-02 |
Amgen Inc. |
Lyophilization method
|
TW202346368A
(en)
|
2022-05-12 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
Multichain multitargeting bispecific antigen-binding molecules of increased selectivity
|
WO2023217987A1
(en)
|
2022-05-12 |
2023-11-16 |
BioNTech SE |
Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
|
GB202207263D0
(en)
|
2022-05-18 |
2022-06-29 |
Annexin Pharmaceuticals Ab |
Therapeutic compositions
|
WO2023225661A1
(en)
|
2022-05-20 |
2023-11-23 |
Bristol-Myers Squibb Company |
Macrocyclic immunomodulators
|
WO2023235380A1
(en)
|
2022-06-01 |
2023-12-07 |
Zikani Therapeutics, Inc. |
Macrolides for treating genetic diseases
|
WO2023240189A1
(en)
|
2022-06-10 |
2023-12-14 |
Bristol-Myers Squibb Company |
Tetrahydropyrido 3,4-d pyrimidine derivatives as kras inhibitors
|
WO2023240188A1
(en)
|
2022-06-10 |
2023-12-14 |
Bristol-Myers Squibb Company |
Pyrido[4,3-d]pyrimidine derivatives as kras inhibitors
|
WO2023250513A1
(en)
|
2022-06-24 |
2023-12-28 |
Zikani Therapeutics, Inc. |
13-membered macrolide compounds for treating diseases mediated by abnormal protein translation
|
WO2024026475A1
(en)
|
2022-07-29 |
2024-02-01 |
Modernatx, Inc. |
Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses
|
WO2024026482A1
(en)
|
2022-07-29 |
2024-02-01 |
Modernatx, Inc. |
Lipid nanoparticle compositions comprising surface lipid derivatives and related uses
|
WO2024026487A1
(en)
|
2022-07-29 |
2024-02-01 |
Modernatx, Inc. |
Lipid nanoparticle compositions comprising phospholipid derivatives and related uses
|
WO2024036270A1
(en)
|
2022-08-11 |
2024-02-15 |
Bristol-Myers Squibb Company |
Kras inhibitors
|
WO2024040109A2
(en)
|
2022-08-16 |
2024-02-22 |
Bristol-Myers Squibb Company |
Kras inhibitors
|
WO2024049994A1
(en)
|
2022-09-01 |
2024-03-07 |
Zikani Therapeutics, Inc. |
Treatment of familial adenomatous polyopsis using a 13-membered macrolide
|
WO2024054926A1
(en)
|
2022-09-07 |
2024-03-14 |
Bristol-Myers Squibb Company |
Kras g12d inhibitors
|
WO2024059472A1
(en)
|
2022-09-12 |
2024-03-21 |
Bristol-Myers Squibb Company |
Macrocyclic immunomodulators
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|